Pressure BioSciences (PBIO) 10-K 31 Mar 15 2014 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
	Dec. 31, 2014	Mar. 31, 2015	Jun. 30, 2014
Document And Entity Information
Entity Registrant Name	PRESSURE BIOSCIENCES INC
Entity Central Index Key	830656
Document Type	10-K
Document Period End Date	31-Dec-14
Amendment Flag	FALSE
Current Fiscal Year End Date	-19
Is Entity a Well-known Seasoned Issuer?	No
Is Entity a Voluntary Filer?	No
Is Entity's Reporting Status Current?	Yes
Entity Filer Category	Smaller Reporting Company
Entity Public Float			$4,690,565
Entity Common Stock, Shares Outstanding		19,070,654
.	FY
Document Fiscal Year Focus	2014

CONSOLIDATED_CONDENSED_BALANCE

CONSOLIDATED CONDENSED BALANCE SHEETS (USD $)	Dec. 31, 2014	Dec. 31, 2013
ASSETS
Cash and cash equivalents	$473,948	$31,417
Accounts receivable	272,022	147,635
Inventories, net of reserves of $50,000 at December 31, 2014 and December 31, 2013	850,552	736,676
Prepaid income taxes	7,381	7,381
Prepaid expenses and other current assets	104,204	85,573
TOTAL CURRENT ASSETS	1,708,107	1,008,682
Property and equipment, net	36,025	58,102
Intangible assets, net	0	36,498
TOTAL ASSETS	1,744,132	1,103,282
LIABILITIES AND STOCKHOLDERS' DEFICIT
Accounts payable	1,035,781	1,102,772
Accrued employee compensation	157,347	149,333
Accrued professional fees and other	719,432	615,244
Deferred revenue	27,117	28,189
Promissory note	0	75,000
Related party debt	0	25,182
Convertible debt, net of debt discount of $328,681 at December 31, 2014 and $331,306 at December 31, 2013	1,004,513	281,796
Other debt	80,480	89,989
Warrant derivative liability	159,875	344,570
Conversion option liability	590,341	356,197
TOTAL CURRENT LIABILITIES	3,774,886	3,068,272
Deferred revenue - noncurrent	28,977	2,785
TOTAL LIABILITIES	3,803,863	3,071,057
STOCKHOLDERS' DEFICIT
Series D convertible preferred stock, $.01 par value; 850 shares authorized; 300 shares issued and outstanding on December 31, 2014 and 2013 respectively (Liquidation value of $300,000)	3	3
Series G convertible preferred stock, $.01 par value; 240,000 shares authorized; 86,570 and 145,320 shares issued and outstanding on December 31, 2014 and 2013, respectively	866	1,453
Series H convertible preferred stock $.01 par value 10,000 shares authorized; 10,000 shares issued and outstanding on December 31, 2014 and 2013 respectively	100	100
Series H2 convertible preferred stock $.01 par value 21 shares authorized; 21 shares issued and outstanding on December 31, 2014 and 0 at December 31, 2013	0	0
Series J convertible preferred stock $.01 par value 6,250 shares authorized; 3,546 and 5,088 shares issued and outstanding on December 31, 2014 and 2013, respectively	36	51
Series K convertible preferred stock $.01 par value 15,000 shares authorized; 11,416 and 4,000 shares issued and outstanding on December 31, 2014 and 2013, respectively	114	40
Common stock, $.01 par value; 65,000,000 and 50,000,000 shares authorized; and 18,673,390 shares issued and 17,161,390 outstanding on December 31, 2014 and 12,024,267 issued and outstanding on December 31, 2013	186,734	120,243
Warrants to acquire common stock	5,253,566	4,267,402
Additional paid-in capital	24,617,564	19,509,921
Accumulated deficit	-32,118,714	-25,866,988
Total stockholders' deficit	-2,059,731	-1,967,775
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	$1,744,132	$1,103,282

CONSOLIDATED_CONDENSED_BALANCE1

CONSOLIDATED CONDENSED BALANCE SHEETS (Parenthetical) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Assets
Reserve for inventories, net	$50,000	$50,000
Liabilities
Convertible debt, net	$328,681	$331,306
LIABILITIES AND STOCKHOLDERS' DEFICIT
Series D convertible preferred stock, Par value	$0.01	$0.01
Series D convertible preferred stock, Shares authorized	850	850
Series D convertible preferred stock, Shares Issued	300	300
Series D convertible preferred stock, Shares Outstanding	300	300
Series G convertible preferred stock, Par value	$0.01	$0.01
Series G convertible preferred stock, Shares authorized	240,000	240,000
Series G convertible preferred stock, Shares Issued	86,570	145,320
Series G convertible preferred stock, Shares Outstanding	86,570	145,320
Series H convertible preferred stock, Par value	$0.01	$0.01
Series H convertible preferred stock, Shares authorized	10,000	10,000
Series H convertible preferred stock, Shares Issued	10,000	10,000
Series H convertible preferred stock, Shares Outstanding	10,000	10,000
Series H2 convertible preferred stock, Par value	$0.01	$0.01
Series H2 convertible preferred stock, Shares authorized	21	0
Series H2 convertible preferred stock, Shares Issued	21	0
Series H2 convertible preferred stock, Shares Outstanding	21	0
Series J convertible preferred stock, Par value	$0.01	$0.01
Series J convertible preferred stock, Shares authorized	6,250	6,250
Series J convertible preferred stock, Shares Issued	3,546	5,088
Series J convertible preferred stock, Shares Outstanding	3,546	5,088
Series K convertible preferred stock, Par value	$0.01	$0.01
Series K convertible preferred stock, Shares authorized	15,000	15,000
Series K convertible preferred stock, Shares Issued	11,416	4,000
Series K convertible preferred stock, Shares Outstanding	11,416	4,000
Common stock, par value	$0.01	$0.01
Common stock, shares authorized	65,000,000	50,000,000
Common stock, shares issued	18,673,390	12,024,267
Common stock, shares outstanding	18,673,390	12,024,267

CONSOLIDATED_CONDENSED_STATEME

CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Revenue:
Products, services, other	$1,350,150	$1,046,678
Grant revenue	24,594	456,610
Total revenue	1,374,744	1,503,288
Costs and expenses:
Cost of Products and services	652,438	567,828
Research and development	952,555	1,035,426
Selling and marketing	721,229	752,288
General and administrative	2,386,872	2,474,938
Total operating costs and expenses	4,713,094	4,830,480
Operating loss	-3,338,350	-3,327,192
Other income (expense):
Interest expense, net	-1,303,129	-339,818
Other income (expense), net	-169,554	-531,130
Change in fair value of derivative liability	198,493	113,713
Total other income (expense)	-1,274,190	-757,235
Net loss	-4,612,540	-4,084,427
Accrued and deemed dividends on convertible preferred stock	-1,639,186	-1,163,022
Net loss applicable to common shareholders	($6,251,726)	($5,247,449)
Net loss per share attributable to common stockholders - basic and diluted	($0.44)	($0.44)
Weighted average common stock shares outstanding basic and diluted	14,264,753	11,821,870

Shareholders_Equity

Shareholders Equity (USD $)	Series D Preferred Stock	Series G Preferred Stock	Series H Preferred Stock	Series H2 Preferred Stock	Series J Preferred Stock	Series K Preferred Stock	Common Stock	Warrant	Additional Paid-In Capital	Accumulated Deficit	Total
	USD ($)	USD ($)	USD ($)		USD ($)	USD ($)	USD ($)	USD ($)	USD ($)	USD ($)	USD ($)
Beginning Balance - Amount at Dec. 31, 2012	$3	$1,453
Beginning Balance - Shares at Dec. 31, 2012	300	145,320
Stock-based compensation									136,796		136,796
Fair value of common stock issued for services, Shares							875,000
Fair value of common stock issued for services, Amount							8,750		467,962		476,712
Offering costs for issuance of preferred stock									-67,739		-67,739
Issuance of warrants in connection short-term loans								73,647			73,647
Issuance of warrants for services, Amount								21,028			21,028
Beneficial conversion of issued preferred stock									1,002,602	-1,002,602
Issuance of Series J convertible preferred stock, Shares					5,088
Issuance of Series J convertible preferred stock, Amount					51			885,309	1,149,340		2,034,700
Issuance of Series K convertible preferred stock, Shares						4,000
Issuance of Series K convertible preferred stock, Amount						40		271,422	728,538		1,000,000
Reclassification of conversion option liabilities									141,704		141,704
Conversion of common stock to preferred stock, Shares			10,000				-1,000,000
Conversion of common stock to preferred stock, Amount			100				-10,000		9,900
Dividends earned on preferred stock, Amount										-160,420	-160,420
Net loss										-4,084,427	-4,084,427
Ending Balance, Amount at Dec. 31, 2013	3	1,453	100		51
Ending Balance, Shares at Dec. 31, 2013	300	145,320	10,000		5,088
Stock-based compensation									101,125		101,125
Fair value of common stock issued for services, Shares							588,830
Fair value of common stock issued for services, Amount							5,888		208,304		214,192
Offering costs for issuance of preferred stock									-8,000		-8,000
Issuance of warrants in connection short-term loans								49,599			49,599
Issuance of warrants for services, Shares								93,488			93,488
Issuance of stock in lieu of cash for Board of Director fees, Shares						399
Issuance of stock in lieu of cash for Board of Director fees, Amount						3		24,578	60,169		84,750
Exercise of warrants, Shares							596,658
Exercise of warrants, Amount							5,967		143,198		149,165
Beneficial conversion of issued preferred stock									1,495,415	-1,495,415
Warrant reset, Shares							3,612,000
Warrant reset, Amount							36,120	163,654	662,745		862,519
Conversion of Series G convertible preferred stock, Shares		-58,750					587,500
Conversion of Series G convertible preferred stock, Amount		-587					5,875		-5,288
Conversion of Series J convertible preferred stock, Shares					-1,542		1,541,000
Conversion of Series J convertible preferred stock, Amount					-15		15,410		-15,395
Conversion of Series K convertible preferred stock, Shares						-1,099	1,099,000
Conversion of Series K convertible preferred stock, Amount						-11	10,990		-10,979
Conversion of debt for common stock, Shares							510,000
Conversion of debt for common stock, Amount							5,100		131,400		136,500
Issuance of Series K convertible preferred stock, Shares						8,176
Issuance of Series K convertible preferred stock, Amount						82		654,845	1,592,432		2,247,359
Reclassification of conversion option liabilities									320,338		320,338
Conversion of common stock to preferred stock, Shares				21			-2,100,000
Conversion of common stock to preferred stock, Amount							-21,000		21,000
Reclassification of Series D warrant liability									330,405		330,405
Dividends earned on preferred stock, Amount										-143,771	-143,771
Issuance of common stock for preferred dividends, Shares							214,135
Issuance of common stock for preferred dividends, Amount							2,141		80,774		82,915
Net loss										-4,612,540	-4,612,540
Ending Balance, Amount at Dec. 31, 2014	$3	$866	$100		$36	$114	$186,734	$5,253,566	$24,617,564	($32,118,714)	($2,059,731)
Ending Balance, Shares at Dec. 31, 2014	300	86,570	10,000	21	3,546	11,416	18,673,390

CONSOLIDATED_CONDENSED_STATEME1

CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	($4,612,540)	($4,084,427)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	65,714	79,563
Accretion of non-cash interest and amortization of debt issue costs	1,310,351	708,729
Stock-based compensation expense	101,125	136,796
Amortization of third party fees paid in restricted common stock	307,013	480,492
Amortization of board of director fees paid in preferred stock	84,750	0
Change in fair value of warrant derivative liability	-198,493	-113,713
Changes in operating assets and liabilities:
Accounts receivable	-124,387	68,630
Inventories	-113,876	186,686
Accounts payable	-66,991	-97,074
Accrued employee compensation	8,014	29,995
Deferred revenue and other accrued expenses	47,373	257,387
Prepaid expenses and other current assets	-18,631	4,333
Net cash used in operating activities	-3,210,578	-2,342,603
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of property and equipment	-7,139	-58,749
Net cash used in investing activities	-7,139	-58,749
CASH FLOWS FROM FINANCING ACTIVITIES:
Borrowings on convertible debt, net of issuance costs	1,126,744	1,374,297
Borrowings on related party and other debt, net of issuance costs	302,252	222,000
Repayment of related party and other debt	-416,691	-180,304
Repayment of convertible debt	-303,100	-350,000
Payment of dividends	0	-60,000
Net proceeds from the exercise of common stock warrants	149,165	0
Net proceeds from warrant reset transaction	862,518	0
Net proceeds from the issuance of preferred stock	1,939,360	1,425,315
Net cash provided by financing activities	3,660,248	2,431,308
Change in cash and cash equivalents	442,531	29,956
Cash and cash equivalents, beginning of period	31,417	1,461
Cash and cash equivalents, end of period	473,948	31,417
SUPPLEMENTAL INFORMATION:
Interest paid in cash	14,832	0
Convertible debt exchanged for common stock	136,500	0
Preferred dividends paid with common stock	82,916	0
Convertible debt and accrued interest exchanged for preferred stock	300,000	1,503,530
Incremental value from warrant modifications	163,654	0
Fair value of common stock issued for services	214,192	467,964
Issuance of preferred stock for board fees	84,750	38,126
Beneficial conversion feature on convertible preferred stock	1,495,415	1,002,602
Dividends earned on preferred stock	$143,771	$160,420

1_Business_Overview_Liquidity_

1. Business Overview, Liquidity and Management Plans	12 Months Ended
	Dec. 31, 2014
Notes to Financial Statements
1. Business Overview, Liquidity and Management Plans	We are focused on solving the challenging problems inherent in biological sample preparation, a crucial laboratory step performed by scientists worldwide working in biological life sciences research. Sample preparation is a term that refers to a wide range of activities that precede most forms of scientific analysis. Sample preparation is often complex, time-consuming, and in our belief, one of the most error-prone steps of scientific research. It is a widely-used laboratory undertaking, the requirements of which drive what we believe is a large and growing worldwide market. We have developed and patented a novel, enabling technology platform that can control the sample preparation process. It is based on harnessing the unique properties of high hydrostatic pressure. This process, called pressure cycling technology, or PCT, uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels (35,000 psi or greater) to safely, conveniently and reproducibly control the actions of molecules in biological samples, such as cells and tissues from human, animal, plant, and microbial sources.
	Our pressure cycling technology uses internally developed instrumentation that is capable of cycling pressure between ambient and ultra-high levels - at controlled temperatures and specific time intervals - to rapidly and repeatedly control the interactions of bio-molecules, such as DNA, RNA, proteins, lipids, and small molecules. Our laboratory instrument, the Barocycler®, and our internally developed consumables product line, including PULSE (Pressure Used to Lyse Samples for Extraction) Tubes, other processing tubes, and application specific kits (which include consumable products and reagents) together make up our PCT Sample Preparation System, or PCT SPS.
	We have experienced negative cash flows from operations with respect to our pressure cycling technology business since our inception. As of December 31, 2014, we did not have adequate working capital resources to satisfy our current liabilities. Based on our current projections, including debt and equity financing subsequent to December 31, 2014, we believe our current and projected cash resources will enable us to extend our cash for the foreseeable future.
	These conditions cause substantial doubt regarding our ability to continue as a going concern due to the risk that we may not have sufficient cash and liquid assets at December 31, 2014 to cover our operating and capital requirements for the next twelve-month period; and if sufficient cash cannot be obtained, we would have to substantially alter, or possibly even discontinue, operations. The accompanying financial statements do not include any adjustments that might result from the outcome of this uncertainty.
	The conditions described above could adversely affect our ability to obtain additional financing on favorable terms, if at all, and may cause investors to have reservations about our long-term prospects, and may adversely affect our relationships with customers. If we cannot successfully continue as a going concern, our stockholders may lose their entire investment in us. Although we have successfully completed equity financings and reduced expenses in the past, we cannot assure you that our plans to address these matters in the future will be successful.  If we are not successful there is substantial doubt that we can continue as a going concern.
	Management has developed a plan to continue operations. This plan includes further reductions in expenses and obtaining equity or debt financing. Although we have successfully completed equity financings and reduced expenses in the past, we cannot assure that our plans to address these matters in the future will be successful. Additional financing may not be available to us on a timely basis, if at all, or on terms acceptable to us. In the event we are unable to raise sufficient funds on terms acceptable to us, we may be required to:
	·	severely limit or cease our operations or otherwise reduce planned expenditures and forego other business opportunities, which could harm our business. The accompanying financial statements do not include adjustments that may be required in the event of the disposal of assets or the discontinuation of the business;
	·	obtain financing with terms that may have the effect of diluting or adversely affecting the holdings or the rights of the holders of our capital stock; or
	·	obtain funds through arrangements with future collaboration partners or others that may require us to relinquish rights to some or all of our technologies or products.
	Our common stock is listed on the Over-the-Counter exchange.

2_Summary_of_Significant_Accou

2. Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
2. Summary of Significant Accounting Policies
	i.	Principles of Consolidation
	The consolidated financial statements include the accounts of Pressure BioSciences, Inc., and its wholly-owned subsidiary PBI BioSeq, Inc. All intercompany accounts and transactions have been eliminated in consolidation.
	ii.	Use of Estimates
	To prepare our consolidated financial statements in conformity with accounting principles generally accepted in the United States of America, we are required to make significant estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. In addition, significant estimates were made in projecting future cash flows to quantify impairment of assets, deferred tax assets, the costs associated with fulfilling our warranty obligations for the instruments that we sell, and the estimates employed in our calculation of fair value of stock options awarded, beneficial conversion features and derivative liabilities. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from the estimates and assumptions used.
	iii.	Revenue Recognition
	Revenue is recognized when realized or earned when all the following criteria have been met: persuasive evidence of an arrangement exists; delivery has occurred and risk of loss has passed to the customer; the seller’s price to the buyer is fixed or determinable; and collectability is reasonably assured.
	Our current instruments, the Barocycler NEP3229 and NEP2320, require a basic level of instrumentation expertise to set-up for initial operation. To support a favorable first experience for our customers, we send a highly trained technical representative to the customer site to install every Barocycler that we sell, lease, or rent through our domestic sales force. The installation process includes uncrating and setting up the instrument, followed by introductory user training. Product revenue related to current Barocycler instrumentation is recognized upon the completion of the installation and introductory training process of the instrumentation at the customer location, for domestic installations. Product revenue related to sales of PCT instrumentation to our foreign distributors is recognized upon shipment through a common carrier. We provide for the expected costs of warranty upon the recognition of revenue for the sales of our instrumentation. Our sales arrangements do not provide our customers with a right of return. Product revenue related to the HUB440 and our consumable products such as PULSE Tubes, MicroTubes, and application specific kits is recorded upon shipment through a common carrier. Shipping costs are included in sales and marketing expense. Any shipping costs billed to customers are recognized as revenue.
	We account for our lease agreements under the operating method. We record revenue over the life of the lease term and we record depreciation expense on a straight-line basis over the thirty-six month estimated useful life of the Barocycler instrument. The depreciation expense associated with assets under lease agreement is included in the “Cost of PCT products and services” line item in our consolidated statements of operations. Many of our lease and rental agreements allow the lessee to purchase the instrument at any point during the term of the agreement with partial or full credit for payments previously made. We pay all maintenance costs associated with the instrument during the term of the leases.
	Revenue from government grants is recorded when expenses are incurred under the grant in accordance with the terms of the grant award. Under fixed fee government grants the Company records revenue over the life of the government grant.
	Revenue from service contracts is recorded ratably over the length of the contract.
	Our transactions sometimes involve multiple elements (i.e., products and services). Revenue under multiple element arrangements is recognized in accordance with FASB ASC 605-25 Multiple-Element Arrangements (“ASC 605”). When vendor specific objective evidence or third party evidence of selling price for deliverables in an arrangement cannot be determined, the Company develops a best estimate of the selling price to separate deliverables and allocates arrangement consideration using the relative selling price method. If an arrangement includes undelivered elements that are not essential to the functionality of the delivered elements, we defer the fair value of the undelivered elements to such time as they are delivered. Fair value is determined based upon the price charged when the element is sold separately. If there is not sufficient evidence of the fair value of the undelivered elements the Company uses its best estimate of the value of those items and recognizes revenues based on the relative values of the delivered and undelivered items. We provide certain customers with extended service contracts with revenue recognized ratably over the life of the contract.
	iv.	Cash and Cash Equivalents
	Our policy is to invest available cash in short-term, investment grade interest-bearing obligations, including money market funds, and bank and corporate debt instruments. Securities purchased with initial maturities of three months or less are valued at cost plus accrued interest, which approximates fair value, and are classified as cash equivalents.
	v.	Research and Development
	Research and development costs, which are comprised of costs incurred in performing research and development activities including wages and associated employee benefits, facilities, consumable products and overhead costs that are expensed as incurred. In support of our research and development activities we utilize our Barocycler instruments that are capitalized as fixed assets and depreciated over their expected useful life.
	vi.	Inventories
	Inventories are valued at the lower of cost (average cost) or market (sales price). The cost of Barocyclers consists of the cost charged by the contract manufacturer. The cost of manufactured goods includes material, freight-in, direct labor, and applicable overhead. The composition of inventory as of December 31 is as follows:
			2014				2013
	Raw materials		$	304,928			$	147,290
	Finished goods			595,624				639,386
	Inventory reserve			(50,000	)			(50,000	)
	Total		$	850,552			$	736,676
	vii.	Property and Equipment
	Property and equipment are stated at cost, less accumulated depreciation. For financial reporting purposes, depreciation is recognized using the straight-line method, allocating the cost of the assets over their estimated useful lives of three years for certain laboratory equipment, from three to five years for management information systems and office equipment, and three years for all PCT finished units classified as fixed assets.
	viii.	Intangible Assets
	We have classified as intangible assets, costs associated with the fair value of acquired intellectual property. Intangible assets, including patents, are being amortized on a straight-line basis over sixteen years. We perform an annual review of our intangible assets for impairment. When impairment is indicated, any excess of carrying value over fair value is recorded as a loss. An impairment analysis of intangible assets was performed as of December 31, 2013. Based on this analysis, we concluded that no impairment of intangible assets had occurred.
	ix.	Long-Lived Assets and Deferred Costs
	The Company’s long-lived assets and other assets are reviewed for impairment in accordance with the guidance of the FASB ASC 360-10-05, Property, Plant, and Equipment, whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. Recoverability of an asset to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the asset. If such asset is considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds its fair value. Through December 31, 2014, the Company had not experienced impairment losses on its long-lived assets. While our current and historical operating losses and cash flow are indicators of impairment, we performed an impairment test at December 31, 2014 and determined that such long-lived assets were not impaired.
	x.	Concentrations
	Credit Risk
	Our financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash, cash equivalents and trade receivables. We have cash investment policies which, among other things, limit investments to investment-grade securities. We perform ongoing credit evaluations of our customers, and the risk with respect to trade receivables is further mitigated by the fact that many of our customers are government institutions and university labs. Allowances are provided for estimated amounts of accounts receivable which may not be collected.  At December 31, 2014 and 2013, we determined that no allowance against accounts receivable was necessary.
	The following table illustrates the level of concentration of the below two groups within revenue as a percentage of total revenues during the years ended December 31:
			2014				2013
	Top Five Customers			32	%			53	%
	Federal Agencies			6	%			33	%
	The following table illustrates the level of concentration of the below two groups within accounts receivable as a percentage of total accounts receivable balance as of December 31:
			2014				2013
	Top Five Customers			86	%			86	%
	Federal Agencies			9	%			16	%
	Product Supply
	BIT Group USA, formerly Source Scientific, LLC, has been our sole contract manufacturer for all of our PCT instrumentation. Until we develop a broader network of manufacturers and subcontractors, obtaining alternative sources of supply or manufacturing services could involve significant delays and other costs and challenges, and may not be available to us on reasonable terms, if at all. The failure of a supplier or contract manufacturer to provide sufficient quantities, acceptable quality and timely products at an acceptable price, or an interruption of supplies from such a supplier could harm our business and prospects.
	xi.	Computation of Loss per Share
	Basic loss per share is computed by dividing loss available to common shareholders by the weighted average number of common shares outstanding. Diluted loss per share is computed by dividing loss available to common shareholders by the weighted average number of common shares outstanding plus additional common shares that would have been outstanding if dilutive potential common shares had been issued. For purposes of this calculation, convertible preferred stock, common stock dividends, warrants to acquire preferred stock convertible into common stock, and warrants and options to acquire common stock, are all considered common stock equivalents in periods in which they have a dilutive effect and are excluded from this calculation in periods in which these are anti-dilutive. The following table illustrates our computation of loss per share for the years ended December 31, 2014 and 2013.
			For the Year Ended
			December 31,
			2014				2013
	Numerator:
	Net loss		$	(4,612,540	)		$	(4,084,427	)
	Beneficial conversion feature for preferred stock			(1,495,415	)			(1,002,602	)
	Preferred dividends accrued			(143,771	)			(100,420	)
	Preferred dividends paid in cash			-				(60,000	)
	Net loss applicable to common shareholders		$	(6,251,726	)		$	(5,247,449	)
	Denominator for basic and diluted loss per share:
	Weighted average  common shares outstanding			14,264,753				11,821,870
	Loss per common share - basic and diluted		$	(0.44	)		$	(0.44	)
	The following table presents securities that could potentially dilute basic loss per share in the future. For all periods presented, the potentially dilutive securities were not included in the computation of diluted loss per share because these securities would have been anti-dilutive for the years ended December 31:
			2014				2013
	Stock options			3,406,250				1,771,708
	Convertible debt			5,453,571				2,242,024
	Common stock warrants			19,182,201				15,012,327
	Convertible preferred stock:
	Series D Convertible Preferred			750,000				750,000
	Series G Convertible Preferred			865,700				1,453,200
Series H Convertible Preferred			1,000,000				1,000,000
Series H2 Convertible Preferred			2,100,000				-
Series J Convertible Preferred			3,546,000				5,087,500
Series K Convertible Preferred			11,416,000				4,000,000
			47,719,722				31,316,759
xii.	Accounting for Income Taxes
We account for income taxes under the asset and liability method, which requires recognition of deferred tax assets, subject to valuation allowances, and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting and income tax purposes. The Company considers many factors when assessing the likelihood of future realization of our deferred tax assets, including recent cumulative earnings experience by taxing jurisdiction, expectations of future taxable income or loss, the carry-forward periods available to us for tax reporting purposes, and other relevant factors. A valuation allowance is established if it is more likely than not that all or a portion of the net deferred tax assets will not be realized. If substantial changes in the Company’s ownership should occur, as defined in Section 382 of the Internal Revenue Code, there could be significant limitations on the amount of net loss carry forwards that could be used to offset future taxable income.
xiii.	Accounting for Stock-Based Compensation
We maintain equity compensation plans under which incentive stock options and non-qualified stock options are granted to employees, independent members of our Board of Directors and outside consultants. We recognize equity compensation expense over the requisite service period using the Black-Scholes formula to estimate the fair value of the stock options on the date of grant.
Determining Fair Value of Stock Option Grants
Valuation and Amortization Method - The fair value of each option award is estimated on the date of grant using the Black-Scholes pricing model based on certain assumptions. The estimated fair value of employee stock options is amortized to expense using the straight-line method over the vesting period, which generally is over three years.
Expected Term - The Company uses the simplified calculation of expected life, described in the FASB ASC 718, Compensation-Stock Compensation, as the Company does not currently have sufficient historical exercise data on which to base an estimate of expected term. Using this method, the expected term is determined using the average of the vesting period and the contractual life of the stock options granted.
Expected Volatility - Expected volatility is based on the Company’s historical stock volatility data over the expected term of the award.
Risk-Free Interest Rate - The Company bases the risk-free interest rate used in the Black-Scholes valuation method on the implied yield currently available on U.S. Treasury zero-coupon issues with an equivalent remaining term.
Forfeitures - As required by FASB ASC 718, Compensation-Stock Compensation, the Company records stock-based compensation expense only for those awards that are expected to vest. The Company estimated a forfeiture rate of 5% for awards granted based on historical experience and future expectations of options vesting. We used this historical rate as our assumption in calculating future stock-based compensation expense.
The following table summarizes the assumptions we utilized for grants of stock options to the three sub-groups of our stock option recipients during the twelve months ended December 31, 2014 and 2013:
Assumptions		Non-Employee Board Members			CEO, other Officers and Employees
Expected life		6.0 (yrs)			6.0 (yrs)
Expected volatility		134.75%-141.15%			132.2%-141.15%
Risk-free interest rate		1.90%-2.54%			1.09%-2.54%
Forfeiture rate		5.00%			5.00%
Expected dividend yield		0.00%			0.00%
We recognized stock-based compensation expense of $101,125 and $136,796 for the years ended December 31, 2014 and 2013, respectively. The following table summarizes the effect of this stock-based compensation expense within each of the line items within our accompanying Consolidated Statements of Operations for the years ended December 31:
		2014				2013
Research and development		$	30,550			$	53,509
Selling and marketing			19,792				26,551
General and administrative			50,783				56,736
Total stock-based compensation expense		$	101,125			$	136,796
During the years ended December 31, 2014 and 2013, the total fair value of stock options awarded was $401,617 and $128,642, respectively.
As of December 31, 2014, the total estimated fair value of unvested stock options to be amortized over their remaining vesting period was $323,811. The non-cash, stock based compensation expense associated with the vesting of these options will be $181,992 in 2015, $82,761 in 2016, and $59,058 in 2017.
xiv.	Fair Value of Financial Instruments
Due to their short maturities, the carrying amounts for cash and cash equivalents, accounts receivable, accounts payable, and accrued expenses approximate their fair value. Short-term and long-term liabilities are primarily related to liabilities transferred under contractual arrangements with carrying values that approximate fair value.
xv.	Advertising
Advertising costs are expensed as incurred. We did not spend anything on advertising in 2014 or 2013.
xvi.	Fair Value Measurements
The Company follows the guidance of FASB ASC Topic 820, “Fair Value Measurements and Disclosures” (“ASC 820”) as it related to financial assets and financial liabilities that are recognized or disclosed at fair value in the financial statements on a recurring basis.
The Company generally defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). The Company uses a three-tier fair value hierarchy, which classifies the inputs used in measuring fair values. These tiers include: Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions.
Financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company has determined that it does not have any financial assets measured at fair value and that its financial liabilities are currently all classified within Level 3 in the fair value hierarchy.
The following tables set forth the Company’s financial liabilities that were accounted for at fair value on a recurring basis as of December 31, 2014 and December 31, 2013. The assumptions used to determine fair value of the warrants are contained in the table in Note 9 of the accompanying consolidated financial statements. The development of the unobservable inputs for Level 3 fair value measurements and fair value calculations are the responsibility of the Company’s management.
						Fair value measurements at December 31, 2014 using:
		31-Dec-14				Quoted prices in active markets (Level 1)			Significant other observable inputs (Level 2)			Significant unobservable inputs (Level 3)
Series D common stock Purchase Warrants		$	159,875			$	-		$	-		$	159,875
						Fair value measurements at December 31, 2013 using:
		31-Dec-13				Quoted prices in active markets (Level 1)			Significant other observable inputs (Level 2)			Significant unobservable inputs (Level 3)
Series D common stock Purchase Warrants		$	344,570			$	-		$	-		$	344,570
		January 1,				Change in Fair Value			Reclassification into equity			31-Dec-14
		2014
Series D common stock Purchase Warrants		$	344,570			$	145,710		$	(330,405	)	$	159,875
		1-Jan-13				Change in Fair Value			31-Dec-13
Series D common stock Purchase Warrants		$	160,812			$	183,758		$	344,570
						Fair value measurements at December 31, 2014 using:
		31-Dec-14				Quoted prices in active markets (Level 1)			Significant other observable inputs (Level 2)			Significant unobservable inputs (Level 3)
July 7, 2014 note, conversion option		$	53,673				-			-		$	53,673
July 7, 2014 note, conversion option			70,604				-			-			70,604
August 28, 2014 note, conversion option			25,146				-			-			25,146
September 3, 2014 note, conversion option			95,938				-			-			95,938
September 10, 2014 note, conversion option			99,124				-			-			99,124
September 26, 2014 note, conversion option			92,699				-			-			92,699
November 10, 2014 note, conversion option			74,343										74,343
November 17, 2014 note, conversion option			78,814				-			-			78,814
Embedded conversion options		$	590,341				-			-		$	590,341
		Jan. 1, 2014				Issuance fair value			Change in fair value			Reclassification into equity			Dec. 31, 2014
April 11, 2013 note, conversion option		$	130,734			$	-		$	7,348		$	(138,082	)	$	-
June 26, 2013 note, conversion option			55,307				-			6,118			(61,425	)		-
December 4, 2013 note, conversion option			98,129				-			(98,129	)		-			-
December 23, 2013 note, conversion option			72,027				-			48,804			(120,831	)		-
June 4, 2014 note, conversion option			-				57,071			(57,071	)		-			-
July 7, 2014 note, conversion option			-				64,233			(10,560	)		-			53,673
July 7, 2014 note, conversion option			-				89,926			(19,322	)		-			70,604
August 28, 2014 note conversion option							36,892			(11,746	)					25,146
September 3 2014 note, conversion option			-				122,340			(26,402	)		-			95,938
September 10, 2014 note, conversion option			-				129,710			(30,586	)		-			99,124
September 26, 2014 note, conversion option			-				140,060			(47,361	)		-			92,699
November 10, 2014 note, conversion option							136,021			(61,678	)					74,343
November 17, 2014 note, conversion option			-				122,431			(43,617	)		-			78,814
Embedded conversion options		$	356,197			$	898,684		$	(344,202	)	$	(320,338	)	$	590,341
The assumptions for the binomial pricing model are represented in the table below for the conversion options reflected on a per share common stock equivalent basis.
Assumptions		11-Apr-13				Conversion options revalued at February 10, 2014
Expected life (in months)			12				2
Expected volatility			206.2	%			119.7	%
Risk-free interest rate			0.1	%			0.04	%
Exercise price		$	0.14			$	0.25
Fair value per conversion option		$	0.29			$	0.2
Assumptions		26-Jun-13				Conversion options revalued at February 10, 2014
Expected life (in months)			12				5
Expected volatility			189.2	%			137.9	%
Risk-free interest rate			0.13	%			0.07	%
Exercise price		$	0.17			$	0.25
Fair value per conversion option		$	0.25			$	0.23
Assumptions		4-Dec-13				Conversion options revalued at June 30, 2014
Expected life (in months)			24				1
Expected volatility			170.3	%			77.1	%
Risk-free interest rate			0.3	%			0.02	%
Exercise price		$	0.4			$	0.4
Fair value per conversion option		$	0.16			$	0.02
Assumptions		23-Dec-13				Conversion options revalued at June 23, 2014
Expected life (in months)			36				30
Expected volatility			151.4	%			159.2	%
Risk-free interest rate			0.77	%			0.73	%
Exercise price		$	0.4			$	0.4
Fair value per conversion option		$	0.17			$	0.32
Assumptions		4-Jun-14				Conversion options revalued at Dec. 31, 2014
Expected life (in months)			8				1
Expected volatility			121.8	%			77.4	%
Risk-free interest rate			0.07	%			0.03	%
Exercise price		$	0.45			$	0.45
Fair value per conversion option		$	0.16			$	0
Assumptions		7-Jul-14				Conversion options revalued at Dec. 31, 2014
Expected life (in months)			12				6
Expected volatility			117.9	%			114.7	%
Risk-free interest rate			0.12	%			0.12	%
Exercise price		$	0.21			$	0.16
Fair value per conversion option		$	0.18			$	0.11
Assumptions		7-Jul-14				Conversion options revalued at Dec. 31, 2014
Expected life (in months)			12				6
Expected volatility			117.9	%			114.7	%
Risk-free interest rate			0.12	%			0.12	%
Exercise price		$	0.21			$	0.17
Fair value per conversion option		$	0.18			$	0.11
Assumptions		28-Aug-14				Conversion options revalued at Dec. 31, 2014
Expected life (in months)			6				2
Expected volatility			104.4	%			121.7	%
Risk-free interest rate			0.05	%			0.04	%
Exercise price		$	0.14			$	0.15
Fair value per conversion option		$	0.15			$	0.11
Assumptions		Sept. 3, 2014				Conversion options revalued at Dec.31, 2014
Expected life (in months)			36				32
Expected volatility			153.8	%			154.1	%
Risk-free interest rate			0.99	%			0.88	%
Exercise price		$	0.35			$	0.35
Fair value per conversion option		$	0.24			$	0.19
Assumptions		Sept. 10, 2014				Conversion options revalued at Dec. 31, 2014
Expected life (in months)			12				8
Expected volatility			117.6	%			106.6	%
Risk-free interest rate			0.12	%			0.18	%
Exercise price		$	0.13			$	0.14
Fair value per conversion option		$	0.17			$	0.14
Assumptions		Sept. 26, 2014				Conversion options revalued at Dec. 31, 2014
Expected life (in months)			12				9
Expected volatility			116.6	%			106.2	%
Risk-free interest rate			0.11	%			0.17	%
Exercise price		$	0.16			$	0.15
Fair value per conversion option		$	0.19			$	0.13
Assumptions		Nov. 10, 2014				Conversion options revalued at Dec. 31, 2014
Expected life (in months)			10				8
Expected volatility			104.2	%			106.6	%
Risk-free interest rate			0.1	%			0.18	%
Exercise price		$	0.13			$	0.14
Fair value per conversion option		$	0.23			$	0.14
Assumptions		Nov. 17, 2014				Conversion options revalued at Dec. 31, 2014
Expected life (in months)			12				10
Expected volatility			117.9	%			107.1	%
Risk-free interest rate			0.12	%			0.15	%
Exercise price		$	0.17			$	0.17
Fair value per conversion option		$	0.2			$	0.13

3_Property_and_Equipment_net

3. Property and Equipment, net	12 Months Ended
	Dec. 31, 2014
Property, Plant and Equipment [Abstract]
3. Property and Equipment, net	Property and equipment as of December 31, 2014 and 2013 consisted of the following components:
		December 31,
		2014			2013
	Laboratory and manufacturing equipment	$	226,081		$	226,081
	Office equipment		149,459			142,323
	Leasehold improvements		8,117			8,117
	PCT collaboration, demonstration and leased systems		461,858			461,858
	Total property and equipment		845,515			838,379
	Less accumulated depreciation		(809,490	)		(780,277	)
	Net book value	$	36,025		$	58,102
	Depreciation expense for the years ended December 31, 2014 and 2013 was $29,213 and $30,931, respectively.

4_Intangible_Assets_net

4. Intangible Assets, net	12 Months Ended
	Dec. 31, 2014
Goodwill and Intangible Assets Disclosure [Abstract]
4. Intangible Assets, net	Intangible assets as of December 31, 2014 reflect the purchase price attributable to patents in connection with the 1998 acquisition of BioSeq, Inc. and the PCT business. Acquired PCT patents were being amortized to expense on a straight line basis at the rate of $48,632 per year over their estimated remaining useful lives of approximately 6 years. We performed a review of our intangible assets for impairment. When impairment is indicated, any excess of carrying value over fair value is recorded as a loss. We have concluded that there is no impairment of intangible assets. Intangible assets at December 31, 2014 and 2013 consisted of the following:
		December 31,
		2014			2013
	PCT Patents	$	778,156		$	778,156
	Less accumulated amortization		(778,156	)		(741,658	)
	Net book value	$	-		$	36,498
	Amortization expense for the year ended December 31, 2013 was $48,632 and for the year ended December 31, 2014 was $36,498, at which time the assets were fully amortized.

5_Retirement_Plan

5. Retirement Plan	12 Months Ended
	Dec. 31, 2014
Compensation and Retirement Disclosure [Abstract]
5. Retirement Plan	We provide all of our employees with the opportunity to participate in our retirement savings plan. Our retirement savings plan has been qualified under Section 401(k) of the Internal Revenue Code. Eligible employees are permitted to contribute to the plan through payroll deductions within statutory limitations and subject to any limitations included in the plan. During 2014 and 2013 we contributed $10,022 and $10,377, respectively, in the form of discretionary Company-matching contributions.

6_Income_Taxes

6. Income Taxes	12 Months Ended
	Dec. 31, 2014
Income Tax Disclosure [Abstract]
6. Income Taxes	Tax positions must meet a “more likely than not” recognition threshold at the effective date to be recognized. At December 31, 2014 and 2013, the Company did not have any uncertain tax positions. No interest and penalties related to uncertain tax positions were accrued at December 31, 2014 and 2013.
	We did not record an income tax benefit or provision for the year ended December 31, 2014.
	Significant items making up the deferred tax assets and deferred tax liabilities as of December 31, 2014 and December 31, 2013 are as follows:
		December 31,
	Current deferred taxes	2014			2013
	Inventories	$	19,640		$	19,640
	Other accruals		21,818			23,050
	Less: valuation allowance		(41,458	)		(42,690	)
	Total current deferred tax assets	$	-		$	-
	Long term deferred taxes:
	Accelerated tax depreciation	$	12,162		$	29,511
	Non-cash, stock-based compensation, nonqualified		440,614			387,708
	Goodwill and intangibles		-			(14,337	)
	Operating loss carry forwards and tax credits		9,720,260			8,938,681
	Less: valuation allowance		(10,173,036	)		(9,341,563	)
	Total long term deferred tax assets (liabilities), net		-			-
	Total net deferred tax liabilities	$	-		$	-
	A valuation allowance is established if it is more likely than not that all or a portion of the deferred tax asset will not be realized. Accordingly, a valuation allowance was established in 2014 and 2013 for the full amount of our deferred tax assets due to the uncertainty of realization. We believe based on our projection of future taxable operating income for the foreseeable future, it is more likely than not that we will not be able to realize the benefit of the deferred tax asset at December 31, 2014.
	We have net operating loss carry-forwards for federal income tax purposes of $22,260,000 as of December 31, 2014. Included in these numbers are loss carry-forwards that were obtained through the acquisition of BioSeq, Inc. and are subject to Section 382 NOL limitations. These net operating loss carry-forwards expire at various dates from 2015 through 2035.
	We had net operating loss carry-forwards for state income tax purposes of approximately $16,496,000 at December 31, 2014. These net operating loss carry-forwards expire at various dates from 2015 through 2034.
	We have research and development tax credit carryforwards for federal income tax purposes of approximately $1,019,000 as of December 31, 2014 and research and development tax credit carryforwards for state income tax purposes of approximately $165,000 as of December 31, 2014. The federal credit carryforwards expire at various dates from 2015 through 2034.  The state credit carryforwards expire at various dates from 2014 through 2028.
	In addition, we have federal alternative minimum tax credit carryforwards for federal income tax purposes of approximately $217,000 as of December 31, 2014.  These credits do not expire.
	Our effective income tax (benefit) provision rate was different than the statutory federal income tax (benefit) provision rate as follows for the years ended December 31:
		2014			2013
	Federal tax provision rate		34	%		34	%
	Permanent differences		(2	) %		(3	) %
	State tax expense		0	%		0	%
	Refundable AMT and R&D tax credit		0	%		0	%
	Net operating loss carry back		0	%		0	%
	Valuation allowance		(32	) %		(31	) %
	Effective income tax provision		0	%		0	%

7_Commitments_and_Contingencie

7. Commitments and Contingencies	12 Months Ended
	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
7. Commitments and Contingencies	Operating Leases
	Our corporate office is currently located at 14 Norfolk Avenue, South Easton, Massachusetts 02375.   We are currently paying approximately $4,800 per month for our corporate office. On December 31, 2014 the lease was amended to extend the expiration date to December 31, 2015 at the rate of $4,800 per month.
	Effective January 1, 2010, we entered into a three-year lease agreement with the University of Massachusetts in Boston, pursuant to which we are leasing laboratory and office space on campus at the university for research and development activities. We paid $5,000 per month for the use of these facilities.  In August 2014 the landlord exercised their right to terminate the lease.
	On November 1, 2014 we signed a three year lease for laboratory and office space in Medford, Massachusetts.  The lease calls for lease payments of $3,056 per month subject to annual Cost of Living increases.
	Following is a schedule by years of future minimum rental payments required under operating leases with initial or remaining non-cancelable lease terms in excess of one year as of December 31, 2014:
	2015	$	94,272
	Thereafter		73,344
	Total minimum payments required	$	167,616
	Royalty Commitments
	BioMolecular Assays, Inc.
	In 1996, we acquired our initial equity interest in BioSeq, Inc., which at the time was developing our original pressure cycling technology. BioSeq, Inc. acquired its pressure cycling technology from BioMolecular Assays, Inc. under a technology transfer and patent assignment agreement. In 1998, we purchased all of the remaining outstanding capital stock of BioSeq, Inc., and at such time, the technology transfer and patent assignment agreement was amended to require us to pay BioMolecular Assays, Inc. a 5% royalty on our sales of products or services that incorporate or utilize the original pressure cycling technology that BioSeq, Inc. acquired from BioMolecular Assays, Inc. We are also required to pay BioMolecular Assays, Inc. 5% of the proceeds from any sale, transfer or license of all or any portion of the original pressure cycling technology. These payment obligations terminate in 2016. During the fiscal years ended December 31, 2014 and 2013, we incurred $31,835 and $23,785 in royalties, respectively.
	In connection with our acquisition of BioSeq, Inc., we licensed certain limited rights to the original pressure cycling technology back to BioMolecular Assays, Inc.  This license is non-exclusive and limits the use of the original pressure cycling technology by BioMolecular Assays, Inc. solely for molecular applications in scientific research and development and in scientific plant research and development. BioMolecular Assays, Inc. is required to pay us a royalty equal to 20% of any license or other fees and royalties, but not including research support and similar payments, it receives in connection with any sale, assignment, license or other transfer of any rights granted to BioMolecular Assays, Inc. under the license. BioMolecular Assays, Inc. must pay us these royalties until the expiration of the patents held by BioSeq, Inc. in 1998, which we anticipate will be 2016. We have not received any royalty payments from BioMolecular Assays, Inc. under this license.
	Battelle Memorial Institute
	In December 2008, we entered into an exclusive patent license agreement with the Battelle Memorial Institute ("Battelle"). The licensed technology is described in the patent application filed by Battelle on July 31, 2008 (US serial number 12/183,219). This application includes subject matter related to a method and a system for improving the analysis of protein samples, including through an automated system utilizing pressure and a pre-selected agent to obtain a digested sample in a significantly shorter period of time than current methods, while maintaining the integrity of the sample throughout the preparatory process. Pursuant to the terms of the agreement, we paid Battelle a non-refundable initial fee of $35,000. In addition to royalty payments on net sales on “licensed products”, we are obligated to make minimum royalty payments for each year that we retain the rights outlined in the patent license agreement and we are required to have our first commercial sale of the licensed products within one year following the issuance of the patent covered by the licensed technology. After re-negotiating the contract in 2013 our only obligation for 2014 was a royalty payment of approximately $2,900.  The minimum annual royalty was $4,025 for 2013.
	Target Discovery Inc.
	In March 2010, we signed a strategic product licensing, manufacturing, co-marketing, and collaborative research and development agreement with Target Discovery Inc. (“TDI”). Under the terms of the agreement, we have been licensed by TDI to manufacture and sell a highly innovative line of chemicals used in the preparation of tissues for scientific analysis ("TDI reagents"). The TDI reagents were designed for use in combination with our pressure cycling technology. The companies believe that the combination of PCT and the TDI reagents can fill an existing need in life science research for an automated method for rapid extraction and recovery of intact, functional proteins associated with cell membranes in tissue samples. We did not incur any royalty obligation under this agreement in 2014 or 2013.
	Severance and Change of Control Agreements
	Each of Mr. Schumacher, and Drs. Ting, Lazarev, and Lawrence, executive officers of the Company, are entitled to receive a severance payment if terminated by us without cause. The severance benefits would include a payment in an amount equal to one year of such executive officer’s annualized base salary compensation plus accrued paid time off. Additionally, the officer will be entitled to receive medical and dental insurance coverage for one year following the date of termination.
	Each of these executive officers, other than Mr. Schumacher, is entitled to receive a change of control payment in an amount equal to one year of such executive officer’s annualized base salary compensation, accrued paid time off, and medical and dental coverage, in the event of a change of control of the Company. In the case of Mr. Schumacher, this payment would be equal to two years of annualized base salary compensation, accrued paid time off, and two years of medical and dental coverage. The severance payment is meant to induce the aforementioned executives to remain in the employ of the Company, in general; and particularly in the occurrence of a change in control, as a disincentive to the control change.
	Promissory Note
	On November 4, 2011, the Company entered into an agreement with a former placement agent, pursuant to which the Company and the placement agent released each other of their respective obligations under a prior investment banking agreement.  In connection with this agreement, the Company issued the placement agent a promissory note with an original principal amount of $150,000 and an original maturity date of May 4, 2012.  On February 6, 2014 the $75,000 principal balance remaining and $14,832 of accrued and unpaid interest were paid off in cash.
	Convertible Debt
	Loans in the aggregate amount of$155,000 were received from two individuals in 2013. We accrued interest at a rate of 6% on the loans. These loans, along with $863,000 of other prior outstanding loans and unpaid interest, were converted to the Company 's Series J Convertible Preferred Shares in February 2013.
	On April 11 , 2013, we signed a promissory note in the amount of$275,000. The lender paid $125,000, net of $12,500 of original issue discount, upon closing of the note. The lender paid an additional $50,000, net of$5,000 original issue discount, on June 26, 2013. The balance ofthe Consideration shall be paid in the amounts and the dates as the lender chooses. The note and unpaid interest on the note are due and payable one year from the effective date of each payment. The lender has the right to convert all or part of the unpaid principal and interest into common stock at a conversion price of 60% of the lowest trade price in the 25 trading days prior to conversion after six months from the effective date of each closing. The Company has the right to repay the notes at an y time within six months of the effective date of each closing. If the Company repays the note within 90 days of the effective date interest is 0%. If the note is not repaid within the 90 days a onetime interest charge of 12% will be applied. The Company has reserved at least 6,000,000 shares of common stock for conversion under this note. The Compan y evaluated the terms of this note in accordance with ASC 815-40, Derivatives and Hedging Contracts in Entity's Own Stock. The Company determined that the conversion feature met the definition of a liability and therefore, bifurcated the conversion feature as a derivative liability. The derivative liability is measured at the end of each reporting period and the change in fair value is recorded as other expense or income in the statement of operations. The fair value of the conversion feature was $186,041 at December 31, 2013 and reflected in the conversion option liability line in the consolidated balance sheet. On October 10, 2013, this note was amended to change the lenders right to convert and the borrower 's right to repay to December 10, 2013. On December 10, 2013, this note was amended to change the lenders right to convert and the borrower's right to repay to February 10, 2014.
	The proceeds from the convertible debt issued on April 11, 2013, were allocated between the host debt instrument and the convertible option based on the residual method. The estimated fair value of the convertible option was determined using a binomial formula, resulting in an allocation of$274,840 to the convertible option and accounted for as a liability in the Company's consolidated balance sheet. In accordance with the provisions of ASC815-40, the entire gross proceeds of$137,500 was offset by a debt discount of$137,500 which will be amortized to nterest expense over the twelve month life of the debt. The additional $149,840 adjustment between the convertible option liability and the debt discount was charged directly to other expense.
	The proceeds from the convertible debt issued on June 26, 2013, were allocated between the host debt instrument and the convertible option based on the residual method. The estimated fair value of the convertible option was determined using a binomial formula, resulting in an allocation of $84,146 to the convertible option and accounted for as a liability in the Company 's consolidated balance sheet. In accordance with the provisions of ASC815-40, the entire gross proceeds of$55,000 was offset by a debt discount of $55,000 which will be amortized to interest expense over the twelve month life of the debt. The additional $34,146 adjustment between the convertible option liability and the debt discount was charged directl y to other expense.
	So long as the note is outstanding, the Company shall notify the lender of the issuance of any security with a term more favorable to the holder, and the lender may at its option, include the terms as a part of the transaction documents. Both the April II , 2013 note and the June 26, 2013 note were paid off in February 2014.
	On May 24, 2013, we entered into a Convertible Redeemable Note. The lender paid $97,500, net of$2,500 in legal fees, on the closing date. The note does not bear interest. The $100,000 principal is due on May 24, 2015. At any time six months after the closing date, the lender at its option may convert part, or all, of the note then outstanding into shares of the Company's common stock at a conversion price of70% of the average weighted average price of the common stock for the 10 trading days preceding the conversion date. The Company shall have the right to redeem the note at 120% ofthe unpaid principal if paid within 90 days ofthe issuance day, 130% of the unpaid principal ifrepaid between 91 and 180 days following the issuance day and 150% at any time thereafter. The Company has reserved 1,000,000 shares of common stock for conversion under this note. The Company determined that the conversion feature met the definition of a liability and therefore, bifurcated the conversion feature as a derivative liability. The derivative liability is measured at the end of each reporting period and the change in fair value is recorded as other expense or income in the statement of operations.
	The proceeds from the convertible debt issued on May 24, 2013, were allocated between the host debt instrument and the convertible option based on the residual method. The estimated fair value of the convertible option was determined using a binomial formula, resulting in an allocation of $122,223 to the convertible option and accounted for as a liability in the Company's consolidated balance sheet. In accordance with the provisions of ASC815-40, the entire gross proceeds of $100,000 is offset by a debt discount of $100,000 which will be amortized to interest expense over the twenty-four month life of the debt. The additional $24,723 adjustment between the convertible option liability and the debt discount was charged directly to other expense.
	The entire balance of the debt was repaid on November 22, 2013 and the fair value of the conversion option liability remaining on the balance sheet in the amount of $103,521 was reclassified to additional paid in capital.
	On June 6, 2013, we signed a convertible debenture in the amount of$500,000. The lender paid an initial payment of$213,000 net of a "fmder's fee" discount of$25,000 and $12,000 in legal fees, on the closing date. The lender has the right, any time after six months from the issue date to convert any or part of the outstanding and unpaid principal into shares of the Company's common stock at a price of $0.40 per share subject to adjustments for stock splits, stock dividends or rights offerings. The Company has the right to prepay the debenture for a payment of 120% of the outstanding principal plus accrued and unpaid interest. The Company is required to reserve at least 2.5 times the number of shares actually issuable upon full conversion of this debenture. The Company determined that the conversion feature met the definition of a liability in accordance with ASC 815-40 and therefore bifurcated the conversion feature as a derivative liability. The derivative liability is measured at the end of each reporting period and the difference in fair value is recorded as other expense or income in the statement of operations.
	The proceeds from the convertible debt issued on June 6, 2013, were allocated between the host debt instrument and the convertible option based on the residual method. The estimated fair value of the convertible option was determined using a binomial formula, resulting in an allocation of$158,715 to the convertible option and accounted for as a liability in the Company's condensed consolidated balance sheet. In accordance with the provisions of ASC 815-40, the gross proceeds of $250,000 was offset by a debt discount of $195,715 which will be amortized to interest expense over the twelve month life of the debt.
	On December 26, 2013 the Company entered into a settlement agreement with the lender resulting in the Company paying the lender $300,000 in full satisfaction of the original debenture. The conversion option liability remaining on the balance sheet in the amount of $38,180 was reclassified to additional paid in capital.
	On August 8, 2013 and October 10, 2013, we received $160,000 and $250,000, respectively in a six-month note from an existing shareholder. Terms ofthe note include 18% annual interest, a right to convert the note into the next equity transaction of the Company, at the conversion rate of the equity offering, and a three-year warrant to acquire 160,000 shares of common stock and 250,000 shares of common stock, respectively at $0.40 per share. The relative fair value of the warrants was determined to be $28,722 and $33,824, respectively, which was accounted for as a debt discount and amortized to interest expense over the six-month life of the note. Both of these notes and the accrued interest were converted to our Series K Convertible Preferred Stock on December 12, 2013.
	On December 4, 2013, we signed a convertible debenture in the amount of$223,000. The lender paid an initial payment of $200,000 net of a "original issue" discount of $20,000 and $3,000 in legal fees, on the closing date. The lender has the right at any time from the issue date to convert all or part of the outstanding and unpaid principal into shares of the Company 's common stock at a price of$0.40 per share subject to adjustments for stock splits, stock dividends or rights offerings. The Company has the right to prepay the debenture for a payment of 120% of the outstanding principal plus accrued and unpaid interest. The Company is required to reserve at least 4 times the number of shares actually issuable upon full conversion of this debenture. The Company determined that the conversion feature met the definition of a liability in accordance with ASC 815-40 and therefore bifurcated the conversion feature as a derivative liability. The derivative liability is measured at the end of each reporting period and the difference in fair value is recorded as other expense or income in the statement of operations. The fair value of the conversion feature was $98,129 at December 31, 2013 and reflected in the conversion option liability line in the consolidated balance sheet. In addition the lender received a warrant to purchase 70,000 shares of the Company's common stock at an exercise price of $0.3125 per share. The warrants were valued at $11 ,100 which was allocated to debt discount and will be amortized to interest expense over the twenty-four month life of the debt
	The proceeds from the convertible debt issued on December 4, 2013, were allocated between the host debt instrument and the convertible option based on the residual method. The estimated fair value of the convertible option was determined using a binomial formula, resulting in an allocation of$77,388 to the convertible option and accounted for as a liability in the Company's consolidated balance sheet. In accordance with the provisions of ASC  815-40, the gross proceeds of $223,000 was offset by a debt discount of $11 1,488 which will be amortized to interest expense over the twelve month life of the debt.
	On December 23,2013, we signed a convertible debenture in the amount of$150,000. The lender paid an initial payment of $125,000 net of a "original issue" discount of $15,000 and $10,000 in legal fees, on the closing date the lender has the right, any time from the issue date, to convert any or part of the outstanding and unpaid principal into shares of the Company 's common stock at a price of$0.40 per share subject to adjustments for stock  splits, stock dividends or rights offerings. The Company shall have the right to prepay the debenture for a payment of 120% of the outstanding principal plus accrued and unpaid interest. The Company is required to reserve at least 3 times the number of shares actually issuable upon full conversion of this debenture. The Company determined that the conversion feature met the definition of a liability in accordance with ASC 815-40 and therefore bifurcated the conversion feature as a derivative liability. The derivative liability is measured at the end of each reporting period and the change in fair value is recorded as other expense or income in the statement of operations. The fair value of the conversion feature was $72,027 at December 31, 2013 and reflected in the conversion option liability line in the consolidated balance sheet. Tn addition the lender received 75,000 shares of Company restricted common stock, of which the fair value of $17,250 was charged to debt discount and will be amortized to interest expense over the thirty-six month life of the debt.
	The proceeds from the convertible debt issued on December 23, 2013, were allocated between the host debt instrument and the convertible option based on the residual method. The estimated fair value of the convertible option was determined using a binomial formula, resulting in an allocation of$59,903 to the convertible option and accounted for as a liability in the Company's consolidated balance sheet. In accordance with the provisions of ASC815-40, the gross proceeds of$150,000 was offset by a debt discount of$102,153 which will be amortized to interest expense over the thirty-six month life of the debt.
	A loan in the aggregate amount of $300,000 was received from one individual on January 7, 2014. We granted an original issue discount equal to $30,000 and warrants to purchase 270,000 shares of common stock at $0.3125 per share.   The loan was converted to the Company’s Series K Convertible Preferred Shares in January 2014.
	On May 30, 2014, we signed a convertible debenture in the amount of $400,000.  The lender paid an initial payment of $150,000 net of an original issue discount of $12,162 on June 4, 2014.  A one-time interest charge of 9% will be applied to the principal balance.  The lender has the right, at any time from the issue date to convert any or part of the outstanding and unpaid principal into shares of the Company’s common stock at a price of $0.45 per share subject to adjustments for stock splits, stock dividends or rights offerings.  The Company shall have the right to prepay the debenture for a payment of the outstanding principal plus unpaid interest at any time on or before six months after the effective date.  The Company is required to reserve at least 650,000 shares of common stock for full conversion of this debenture.  The maturity date is eight months after the effective date of each payment. The Company determined that the conversion feature met the definition of a liability in accordance with ASC 815-40 and therefore bifurcated the conversion feature and account for it as a derivative liability.  The fair value of the conversion feature was accounted for as a note discount and will be amortized to interest expense over the life of the loan. The fair value of the conversion feature was $0 at December 31, 2014 and reflected in the conversion option liability line in the consolidated balance sheet.
	The proceeds from the convertible debt issued on June 4, 2014, were allocated between the host debt instrument and the convertible option based on the residual method.  The estimated fair value of the convertible option was determined using a binomial formula, resulting in an allocation of $57,071 to the convertible option and accounted for as a liability in the Company’s   consolidated balance sheet. In accordance with the provisions of ASC 815-40, the gross proceeds of $162,162 is offset by a debt discount of $69,233 which will be amortized to interest expense over the eight month life of the debt.
	On July 7, 2014, we signed two convertible debentures in the amount of $180,000.  The lenders paid initial payments of $66,750 and $100,000 net of fees of $8,250 and $5,000 on July 7, 2014. The Company also incurred a $6,000 finder’s fee.  Interest accrues at the rate of 4% on the outstanding principal balance.  They have the right, at any time after 180 days from the issue date to convert any or part of the outstanding and unpaid principal and interest into shares of the Company’s common stock at a price of 65% of the lowest VWAP price of the Company’s shares during the 15 day period prior to conversion subject to adjustments for stock splits, stock dividends or rights offerings.  The Company shall have the right to prepay the debenture for a payment of the outstanding principal plus unpaid interest at any time on or before six months after the effective date.  If the notes are prepaid before the 90th day following the effective date the prepayment is 119% of the principal amount plus accrued and unpaid interest and if prepaid between the 91st day and 180th day from the effective date the prepayment is 133% of the principal amount plus accrued and unpaid interest.  The maturity date is twelve months after the effective date of each payment. The Company determined that the conversion features on each note met the definition of a liability in accordance with ASC 815-40 and therefore bifurcated the conversion feature and account for it as a derivative liability.  The fair value of the conversion features are accounted for as a note discount and will be amortized to interest expense over the life of the loans. The fair value of the conversion features was $124,275 at December 31, 2014 and reflected in the conversion option liability line in the consolidated balance sheet.
	The proceeds from the convertible debt issued on July 7, 2014, were allocated between the host debt instrument and the convertible option based on the residual method.  The estimated fair value of the convertible option was determined using a binomial formula, resulting in an allocation of $154,159 to the convertible option and accounted for as a liability in the Company’s consolidated balance sheet. In accordance with the provisions of ASC 815-40, the gross proceeds of $180,000 is offset by a debt discount of $173,409 which will be amortized to interest expense over the twelve month life of the debt.
	The outstanding principal balance, prepayment penalties and all outstanding accrued interest on these two notes, totaling $242,973, were paid back in January 2015.
	On August 28, 2014 the Company signed a note with a lender for $35,000 and received $32,900 in cash after deducting $2,100 in fees. The Company has the right to prepay the note prior to the maturity date of February 28, 2015 for $45,500.  If the note is not prepaid by the maturity date the note can be converted to Company common shares for 60% of the lowest intra-day trading price for the 15 days prior to the conversion. The difference between the pre-payment price of $45,500 and the cash received is being accounted for as debt discount and amortized to interest expense over the six month life of the note. The Company determined that the conversion features on each note met the definition of a liability in accordance with ASC 815-40 and therefore bifurcated the conversion feature and accounted for it as a derivative liability.  The fair value of the conversion features are accounted for as a note discount and will be amortized to interest expense over the life of the loans. The fair value of the conversion features was $25,146 at December 31, 2014 and reflected in the conversion option liability line in the consolidated balance sheet.
	The proceeds from the convertible debt issued on August 28, 2014, were allocated between the host debt instrument and the convertible option based on the residual method.  The estimated fair value of the convertible option was determined using a binomial formula, resulting in an allocation of $36,892 to the convertible option and accounted for as a liability in the Company’s   consolidated balance sheet. In accordance with the provisions of ASC 815-40, the gross proceeds of $45,500 is offset by a debt discount of $45,500 which will be amortized to interest expense over the twelve month life of the debt. The residual amount of debt discount of $3,992 in excess of the gross proceeds was charged to other income.
	The outstanding principal balance and the prepayment penalty, totaling $45,500, were paid off in February of 2015.
	On September 3, 2014, we signed a convertible debenture in the amount of $175,000.  The lender paid an initial payment of $150,000 net of an original issue discount of $17,500 on September 3, 2014 and fees of $7,500.  The Company also paid fees of $8,000 and gave the lender 75,000 shares of Company common stock valued at $21,750.  Interest will not accrue on this note.  The lender has the right, at any time within 180 days from the issue date to convert any or part of the outstanding and unpaid principal into shares of the Company’s common stock at a price of $0.35 per share subject to adjustments for stock splits, stock dividends or rights offerings.  After 180 days from the issue date the note can be converted at 65% of the lowest closing price for the 20 days preceding the conversion.  The Company shall have the right to prepay the debenture for a payment of 100% of the outstanding principal at any time on or before 90 days after the effective date.  Prepayment after 90 days are subject to a premium ranging from 120% - 140% of the outstanding principal. The maturity date is twelve months after the effective date of each payment. The Company determined that the conversion feature met the definition of a liability in accordance with ASC 815-40 and therefore bifurcated the conversion feature and account for it as a derivative liability.  The fair value of the conversion feature was accounted for as a note discount and will be amortized to interest expense over the life of the loan. The fair value of the conversion feature was $95,938 at December 31, 2014 and reflected in the conversion option liability line in the consolidated balance sheet.
	The proceeds from the convertible debt issued on September 3, 2014, were allocated between the host debt instrument and the convertible option based on the residual method.  The estimated fair value of the convertible option was determined using a binomial formula, resulting in an allocation of $122,340 to the convertible option and accounted for as a liability in the Company’s   consolidated balance sheet. In accordance with the provisions of ASC 815-40, the gross proceeds of $175,000 is offset by a debt discount of $169,090 which will be amortized to interest expense over the twelve month life of the debt.
	The outstanding principal balance and the prepayment penalty on this note, totaling $218,750, were paid back in March 2015.
	On September 10, 2014, we signed a convertible debenture in the amount of $175,000.  The lender paid an initial payment of $92,000 net of an $8,000 fee on September 10, 2014.  Interest will accrue at the rate of 8% on the unpaid principal balance.  The lender has the right, at any time after 180 days from the issue date to convert any or part of the outstanding and unpaid principal and accrued interest into shares of the Company’s common stock at a price equal to 55% of the lowest closing price for the 20 day period preceding the conversion, subject to adjustments for stock splits, stock dividends or rights offerings.  The Company shall have the right to prepay the debenture for a payment of the outstanding principal plus unpaid interest at any time from the effective date to the maturity date for 135% of the principal.  The maturity date is twelve months after the effective date of each payment. The Company determined that the conversion feature met the definition of a liability in accordance with ASC 815-40 and therefore bifurcated the conversion feature and account for it as a derivative liability.  The fair value of the conversion feature was accounted for as a note discount and will be amortized to interest expense over the life of the loan. The fair value of the conversion feature was $99,124 at December 31, 2014 and reflected in the conversion option liability line in the consolidated balance sheet.
	The proceeds from the convertible debt issued on September 10, 2014, were allocated between the host debt instrument and the convertible option based on the residual method.  The estimated fair value of the convertible option was determined using a binomial formula, resulting in an allocation of $129,710 to the convertible option and accounted for as a liability in the Company’s consolidated balance sheet. In accordance with the provisions of ASC 815-40, the gross proceeds of $100,000 is offset by a debt discount of $100,000 which will be amortized to interest expense over the twelve month life of the debt. The residual amount of debt discount of $37,710 in excess of the principal of $100,000 is charged to other expense on the consolidated statement of operations.
	The outstanding principal balance, prepayment penalties and all outstanding accrued interest on this note, totaling $138,978, were paid back in March 2015.
	On September 26, 2014, we signed a convertible debenture in the amount of $113,000.  The lender paid an initial payment of $101,660 net of an original issue discount of $11,340.  A one-time interest charge of 9% will be applied to the principal balance.  The lender has the right, at any time after 179 days from the issue date, to convert any or part of the outstanding and unpaid principal into shares of the Company’s common stock at a 40% discount to the three lowest trading prices in the ten days preceding the conversion subject to adjustments for stock splits, stock dividends or rights offerings.  The Company shall have the right to prepay the debenture for a payment of 135% of the outstanding principal plus unpaid interest at any time on or before six months after the effective date.  The Company is required to reserve at least 650,000 shares of common stock for full conversion of this debenture.  The maturity date is eight months after the effective date of each payment. The Company determined that the conversion feature met the definition of a liability in accordance with ASC 815-40 and therefore bifurcated the conversion feature and account for it as a derivative liability.  The fair value of the conversion feature was accounted for as a note discount and will be amortized to interest expense over the life of the loan. The fair value of the conversion feature was $92,699 at December 31, 2014 and reflected in the conversion option liability line in the consolidated balance sheet.
	The proceeds from the convertible debt issued on September 26, 2014, were allocated between the host debt instrument and the convertible option based on the residual method.  The estimated fair value of the convertible option was determined using a binomial formula, resulting in an allocation of $140,060 to the convertible option and accounted for as a liability in the Company’s consolidated balance sheet. In accordance with the provisions of ASC 815-40, the gross proceeds of $113,000 is offset by a debt discount of $113,000 which will be amortized to interest expense over the twelve month life of the debt. The residual amount of debt discount of $38,400 in excess of the principal of $113,000 is charged to other expense on the consolidated statement of operations.
	On November 10, 2014, we took an additional $75,000 advance on the $175,000 note we signed on September 10, 2014.  Interest will accrue at the rate of 8% on the unpaid principal balance.  The lender has the right, at any time after 180 days from the issue date to convert any or part of the outstanding and unpaid principal and accrued interest into shares of the Company’s common stock at a price equal to 55% of the lowest closing price for the 20 day period preceding the conversion, subject to adjustments for stock splits, stock dividends or rights offerings.  The Company shall have the right to prepay the debenture for a payment of the outstanding principal plus unpaid interest at any time from the effective date to the maturity date for 135% of the principal.  The maturity date is twelve months after the effective date of each payment. The Company determined that the conversion feature met the definition of a liability in accordance with ASC 815-40 and therefore bifurcated the conversion feature and account for it as a derivative liability.  The fair value of the conversion feature was accounted for as a note discount and will be amortized to interest expense over the life of the loan. The fair value of the conversion feature was $74,343 at December 31, 2014 and reflected in the conversion option liability line in the consolidated balance sheet.
	The proceeds from the convertible debt advanced on November 10, 2014, were allocated between the host debt instrument and the convertible option based on the residual method.  The estimated fair value of the convertible option was determined using a binomial formula, resulting in an allocation of $136,021 to the convertible option and accounted for as a liability in the Company’s consolidated balance sheet. In accordance with the provisions of ASC 815-40, the gross proceeds of $75,000 is offset by a debt discount of $6,000 which will be amortized to interest expense over the twelve month life of the debt. The residual amount of debt discount of $67,021 in excess of the principal of $75,000 is charged to other expense on the consolidated statement of operations.
	On November 17, 2014, we signed a convertible debenture in the amount of $105,000.  The lender paid an initial payment $100,000 net of an original debt discount of $5,000. Interest accrues at the rate of 4% on the outstanding principal balance.  The lender has the right, at any time after 180 days from the issue date to convert any or part of the outstanding and unpaid principal and interest into shares of the Company’s common stock at a price of 65% of the lowest VWAP price of the Company’s shares during the 15 day period prior to conversion subject to adjustments for stock splits, stock dividends or rights offerings.  The Company shall have the right to prepay the debenture for a payment of the outstanding principal plus unpaid interest at any time on or before six months after the effective date.  If the note is prepaid before the 90th day following the effective date the prepayment is 119% of the principal amount plus accrued and unpaid interest and if prepaid between the 91st day and 180th day from the effective date the prepayment is 133% of the principal amount plus accrued and unpaid interest.  The maturity date is twelve months after the effective date of each payment. The Company determined that the conversion features on the note met the definition of a liability in accordance with ASC 815-40 and therefore bifurcated the conversion feature and account for it as a derivative liability.  The fair value of the conversion features is accounted for as a note discount and will be amortized to interest expense over the life of the loan. The fair value of the conversion features was $78,814 at December 31, 2014 and reflected in the conversion option liability line in the consolidated balance sheet.
	The proceeds from the convertible debt issued on November 17, 2014, was allocated between the host debt instrument and the convertible option based on the residual method.  The estimated fair value of the convertible option was determined using a binomial formula, resulting in an allocation of $122,431 to the convertible option and accounted for as a liability in the Company’s   consolidated balance sheet. In accordance with the provisions of ASC 815-40, the gross proceeds of $105,000 is offset by a debt discount of $105,000 which will be amortized to interest expense over the twelve month life of the debt. The residual amount of debt discount of $22,431 in excess of the principal of $105,000 is charged to other expense on the consolidated statement of operations.
	Other Notes
	On August 23, 2013 we signed a Merchant Agreement with Strategic Funding Source inc. ("SFS"). Under the agreement we received $75,000 in exchange for rights to all customer receipts until SFS is paid $99,000 to be collected at a rate of $849 per business day. The payments are secured by essentially all tangible assets of the Company. On August 28, 2013 the agreement was modified to give the Company the right to pre-pay the note at any time prior to January 21, 2014. If pre-paid, the Company will receive a discount based on the date of the pre-payment after the funding date. Discounts range from $16,500, if pre-paid within 30 days of funding to $1,500 if pre-paid within 150 days of funding. The note was pre-paid on December 10, 2013.
	On December 10, 2013, we signed a Merchant Agreement with Scripline LLC. Under the agreement we received $96,000 in exchange for rights to all customer receipts until Scripline LLC is paid $126,700, to be collected at the rate of $874 per business day. The payments are secured by essentially all tangible assets of the Company. The outstanding balance was recorded as other debt on the balance sheet.
	On June 6, 2014, we signed a Merchant Agreement with On Deck Capital. Under the agreement we received $150,000 in exchange for rights to all customer receipts until On Deck Capital is paid $190,499, to be collected at the rate of $756 per business day. The payments are secured by essentially all tangible assets of the Company. The Company paid On Deck Capital $3,750 in fees related to this transaction. The outstanding balance is recorded as other debt on the balance sheet. $26,100 of the proceeds were used to pay off the Scripline LLC outstanding balance.
	On June 23, 2014 the Company received $50,000 on a short term interest free note from a lender.  This note was repaid on July 4, 2014.
On July 31, 2014, we signed a Merchant Agreement with a lender. Under the agreement we received $75,000 in exchange for rights to all customer receipts until the lender is paid $101,260, to be collected at the rate of $632 per business day. The payments are secured by essentially all tangible assets of the Company. The Company paid the lender $999 in fees related to this transaction. The remaining outstanding balance under this agreement was paid off in December 2014.
On November 12, 2014 thru November 17, 2014 the Company received and aggregate of $32,000 in short term interest free and unsecured loans from two employees and one outside lender.  $26,000 of these loans were repaid at December 31, 2014.

8_Transactions_with_Related_Pe

8. Transactions with Related Persons	12 Months Ended
	Dec. 31, 2014
Related Party Transactions [Abstract]
8. Transactions with Related Persons	From time to time Mr. Richard T. Schumacher, the Company’s President and CEO, makes loans to the Company to provide the Company with operating cash. The balance of these loans at December 31, 2014 was $6,000.
	On January 28, 2014, Mr. Schumacher invested $10,000 in our Series K Offering of convertible preferred stock and warrants to purchase shares of common stock, for 40 shares of convertible Preferred Stock (convertible into 40,000 shares of common stock) and a Warrant to purchase 20,000 shares of common stock at an exercise price of $0.3125 per share.
	On January 28, 2014, Mr. Jeffrey Peterson, invested $17,250 in our Series K Offering of convertible preferred stock and warrants to purchase shares of common stock, for 69 shares of convertible Preferred Stock (convertible into 69,000 shares of common stock) and a Warrant to purchase 34,500 shares of common stock at an exercise price of $0.3125 per share.
	On January 28, 2014, Mr. Vito Mangiardi, invested $22,500 in our Series K Offering of convertible preferred stock and warrants to purchase shares of common stock, for 90 shares of convertible Preferred Stock (convertible into 90,000 shares of common stock) and a Warrant to purchase 45,000 shares of common stock at an exercise price of $0.3125 per share.
	On January 28, 2014, Mr. Kevin Pollack, invested $22,500 in our Series K Offering of convertible preferred stock and warrants to purchase shares of common stock, for 90 shares of convertible Preferred Stock (convertible into 90,000 shares of common stock) and a Warrant to purchase 45,000 shares of common stock at an exercise price of $0.3125 per share.
	On January 28, 2014, Dr. Mickey Urdea, invested $22,500 in our Series K Offering of convertible preferred stock and warrants to purchase shares of common stock, for 90 shares of convertible Preferred Stock (convertible into 90,000 shares of common stock) and a Warrant to purchase 45,000 shares of common stock at an exercise price of $0.3125 per share.
	On November 12, 2014, Mr. Schumacher invested $5,000 in our Series K Offering of convertible preferred stock and warrants to purchase shares of common stock, for 20 shares of convertible Preferred Stock (convertible into 20,000 shares of common stock) and a Warrant to purchase 10,000 shares of common stock at an exercise price of $0.3125 per share.
	On November 12, 2014, Mr. Jeffrey Peterson, invested $13,000 in our Series K Offering of convertible preferred stock and warrants to purchase shares of common stock, for  shares of convertible Preferred Stock (convertible into 69,000 shares of common stock) and a Warrant to purchase 34,500 shares of common stock at an exercise price of $0.3125 per share.
	On November 12, 2014, Mr. Vito Mangiardi, invested $5,000 in our Series K Offering of convertible preferred stock and warrants to purchase shares of common stock, for 20 shares of convertible Preferred Stock (convertible into 20,000 shares of common stock) and a Warrant to purchase 10,000 shares of common stock at an exercise price of $0.3125 per share.
	On November 12, 2014, Mr. Kevin Pollack, invested $5.000 in our Series K Offering of convertible preferred stock and warrants to purchase shares of common stock, for 20 shares of convertible Preferred Stock (convertible into 20,000 shares of common stock) and a Warrant to purchase 10,000 shares of common stock at an exercise price of $0.3125 per share.
	On November 12, 2014, Dr. Mickey Urdea, invested $5,000 in our Series K Offering of convertible preferred stock and warrants to purchase shares of common stock, for 20 shares of convertible Preferred Stock (convertible into 20,000 shares of common stock) and a Warrant to purchase 10,000 shares of common stock at an exercise price of $0.3125 per share.
	On December 23, 2014, Mr. Schumacher participated in a warrant reset agreement in order to re-price his Common Stock Purchase Warrants. Mr. Schumacher exercised 34,350 warrants for a total of $8,587 and received 34,350 shares of common stock and 34,350 new warrants at an exercise price of $0.40 per common share.
	On December 23, 2014, Mr. Peterson participated in a warrant reset agreement in order to re-price his Common Stock Purchase Warrants. Mr. Peterson exercised 23,000 warrants for a total of $5,750 and received 23,000 shares of common stock and 23,000 new warrants at an exercise price of $0.40 per common share.
	On December 23, 2014, Mr. Mangiardi participated in a warrant reset agreement in order to re-price his Common Stock Purchase Warrants. Mr. Mangiardi exercised 20,000 warrants for a total of $5,000 and received 20,000 shares of common stock and 20,000 new warrants at an exercise price of $0.40 per common share.
	On December 23, 2014, Mr. Pollack participated in a warrant reset agreement in order to re-price his Common Stock Purchase Warrants. Mr. Pollack exercised 40,000 warrants for a total of $10,000 and received 40,000 shares of common stock and 40,000 new warrants at an exercise price of $0.40 per common share.
	On December 23, 2014, Mr. Urdea participated in a warrant reset agreement in order to re-price his Common Stock Purchase Warrants. Mr. Urdea exercised 57,000 warrants for a total of $14,250 and received 57,000 shares of common stock and 57,000 new warrants at an exercise price of $0.40 per common share.

9_Stockholders_Deficit

9. Stockholders' (Deficit)	12 Months Ended
	Dec. 31, 2014
Equity [Abstract]
9. Stockholders' (Deficit)	Preferred Stock
	We are authorized to issue 1,000,000 shares of preferred stock with a par value of $0.01. Of the 1,000,000 shares of preferred stock:
	1)	20,000 shares have been designated as Series A Junior Participating Preferred Stock (“Junior A”)
	2)	313,960 shares have been designated as Series A Convertible Preferred Stock (“Series A”)
	3)	279,256 shares have been designated as Series B Convertible Preferred Stock (“Series B”)
	4)	88,098 shares have been designated as Series C Convertible Preferred Stock (“Series C”)
	5)	850 shares have been designated as Series D Convertible Preferred Stock (“Series D”)
	6)	500 shares have been designated as Series E Convertible Preferred Stock (“Series E”)
	7)	240,000 shares have been designated as Series G Convertible Preferred Stock (“Series G”)
	8)	10,000 shares have been designated as Series H Convertible Preferred Stock (“Series H”)
	9)	21 shares have been designated as Series H2 Convertible Preferred Stock (“Series H2”)
	10)	6,250 shares have been designated as Series J Convertible Preferred Stock (“Series J”)
	11)	15,000 shares have been designated as Series K Convertible Preferred Stock (“Series K”)
	As of December 31, 2014, there were no shares of Junior A, and Series A, B, C, and E issued and outstanding.
	Series D Convertible Preferred Stock
	On November 11, 2011, we completed a registered direct offering, pursuant to which we sold an aggregate of 843 units for a purchase price of $1,000 per unit, resulting in gross proceeds to us of $843,000 (the “Series D Placement”). Each unit (“Series D Unit”) consisted of (i) one share of Series D Convertible Preferred Stock, $0.01 par value per share (the “Series D Convertible Preferred Stock”) convertible into 1,538.46 shares of our  common stock, (subject to adjustment for stock splits, stock dividends, recapitalization, etc.) and (ii) one five-year warrant to purchase approximately 614 shares of our  common stock at a per share exercise price of $0.81, subject to adjustment as provided in the Warrants (“Series D Warrant”). The Series D Warrants will be exercisable beginning on May 11, 2012 and until the close of business on the fifth anniversary of the initial exercise date.
	We engaged an investment banker to assist with the Series D Placement. In connection with the Series D Placement, we paid the investment banker a fee of approximately $67,000 cash.
	The proceeds from the sale of each Series D Unit were allocated between the Series D Convertible Preferred Stock and the Series D Warrants based on the residual method. The estimated fair value of the Series D Warrants was determined using a binomial formula, resulting in an allocation of the gross proceeds of $283,725 to the total warrants issued. The allocation of the gross proceeds to the Series D Convertible Preferred Stock was $559,275. In accordance with the provisions of ASC 470-20, an additional adjustment between Additional Paid in Capital and Accumulated Deficit of $530,140 was recorded to reflect an implicit non-cash dividend related to the allocation of proceeds between the stock and warrants issued. The $530,140 represents the value of the adjustment to additional paid in capital related to the beneficial conversion feature of the Series D Convertible Preferred Stock. The value adjustment was calculated by subtracting the fair market value of the underlying common stock on November 10, 2011 issuable upon conversion of the Series D Convertible Preferred Stock from the fair market value of the Series D Convertible Preferred Stock as determined when the Company performed a fair market value allocation of the proceeds to the Series D Convertible Preferred Stock and warrants. The warrants are recorded as a liability. See “Warrant Derivative Liability” below.
	The Series D Convertible Preferred Stock will rank senior to the Company’s common stock and Series C Convertible Preferred Stock with respect to payments made upon liquidation, winding up or dissolution. Upon any liquidation, dissolution or winding up of the Company, after payment of the Company’s debts and liabilities, and before any payment is made to the holders of any junior securities, the holders of Series D Convertible Preferred Stock will first be entitled to be paid $1,000 per share subject to adjustment for accrued but unpaid dividends.
	We may not pay any dividends on shares of common stock unless we also pay dividends on the Series D Convertible Preferred Stock in the same form and amount, on an as-if-converted basis, as dividends actually paid on shares of our common stock. Except for such dividends, no other dividends may be paid on the Series D Convertible Preferred Stock.
	Each share of Series D Convertible Preferred Stock is convertible into 1,538.46 shares of  common stock (based upon an initial conversion price of $0.65 per share) at any time at the option of the holder, subject to adjustment for stock splits, stock dividends, combinations, and similar recapitalization transactions (the “Series D Conversion Ratio”). Subject to certain exceptions, if the Company issues any shares of  common stock or  common stock equivalents at a per share price that is lower than the conversion price of the Series D Convertible Preferred Stock, the conversion price will be reduced to the per share price at which such shares of  common stock or common stock equivalents are issued. Each share of Series D Convertible Preferred Stock will automatically be converted into shares of  common stock at the Series D Conversion Ratio then in effect if, after six months from the closing of the Series D Placement, the  common stock trades on the OTC Market (or other primary trading market or exchange on which the  common stock is then traded) at a price equal to at least 300% of the then effective Series D Convertible Preferred Stock conversion price for 20 out of 30 consecutive trading days with each trading day having a volume of at least $50,000. Unless waived under certain circumstances by the holder of the Series D Convertible Preferred Stock, such holder’s Series D Convertible Preferred Stock may not be converted if upon such conversion the holder’s beneficial ownership would exceed certain thresholds.
	In addition, in the event we consummate a merger or consolidation with or into another person or other reorganization event in which our shares of  common stock are converted or exchanged for securities, cash or other property, or we sell, lease, license or otherwise dispose of all or substantially all of our assets or we or another person acquire 50% or more of our outstanding shares of  common stock, then following such event, the holders of the Series D Convertible Preferred Stock will be entitled to receive upon conversion of the Series D Convertible Preferred Stock the same kind and amount of securities, cash or property which the holders of the Series D Convertible Preferred Stock would have received had they converted the Series D Convertible Preferred Stock immediately prior to such fundamental transaction.
	The holders of Series D Convertible Preferred Stock are not entitled to vote on any matters presented to the stockholders of the Company for their action or consideration at any meeting of stockholders of the Company (or by written consent of stockholders in lieu of meeting), except that the holders of Series D Convertible Preferred Stock may vote separately as a class on any matters that would (i) amend, our Restated Articles of Organization, as amended, in a manner that adversely affects the rights of the Series D Convertible Preferred Stock, (ii) alter or change adversely the powers, preferences or rights of the Series D Convertible Preferred Stock or alter or amend the certificate of designation, (iii) authorize or create any class of shares ranking as to dividends, redemption or distribution of assets upon liquidation senior to, or otherwise pari passu with, the Series D Convertible Preferred Stock, or (iv) increase the number of authorized shares of Series D Convertible Preferred Stock.
	If, within 12 months of the initial issuance of the Series D Convertible Preferred Stock, we issue any  common stock,  common stock equivalents, indebtedness or any combination thereof (a “Subsequent Financing”), the holders of Series D Convertible Preferred Stock will have the right to participate on a pro-rata basis in up to 50% of such Subsequent Financing.
	Series D Warrants
	The Series D Warrants originally had an exercise price equal to $0.81 per share of common stock.  In April 2012, the number of Series D Warrants increased by 530,406 to a total of 1,047,875 and each Series D Warrant had an exercise price reset to $0.40 per share of common stock.  In December of 2013 the number of Series D Warrants increased by 628,733 to a total of 1,676,608 and each Series D Warrant had an exercise price reset to $0.25 per share of common stock. The Series D Warrants will be exercisable beginning on the six month anniversary of the date of issuance and expire five years from the initial exercise date.  The Series D Warrants permit the holder to conduct a “cashless exercise” at any time a registration statement registering, or the prospectus contained therein, is not available for the issuance of the shares of common stock issuable upon exercise of the Series D Warrant, and under certain circumstances at the expiration of the Series D Warrants. The exercise price and/or number of shares of common stock issuable upon exercise of the Series D Warrants are subject to adjustment for certain stock dividends, stock splits or similar capital reorganizations, as set forth in the Warrants.  The exercise price is also subject to adjustment in the event that we issue any shares of common stock or common stock equivalents at a per share price that is lower than the exercise price for the Series D Warrants then in effect.  Upon any such issuance, subject to certain exceptions, the exercise price will be reduced to the per share price at which such shares of common stock or common stock equivalents are issued and number of Series D Warrant shares issuable thereunder shall be increased such that the aggregate exercise price payable thereunder, after taking into account the decrease in the exercise price, shall be equal to the aggregate exercise price prior to such adjustment.  Unless waived under certain circumstance by the holder of a Series D Warrant, such holder may not exercise the Series D Warrant if upon such exercise the holder’s beneficial ownership of the Company’s common stock would exceed certain thresholds.
	In the event we consummate a merger or consolidation with or into another person or other reorganization event in which our shares of  common stock are converted or exchanged for securities, cash or other property, or we sell, lease, license or otherwise dispose of all or substantially all of our assets or we or another person acquire 50% or more of our outstanding shares of  common stock, then following such event, the holders of the Series D Warrants will be entitled to receive upon exercise of the Series D Warrants the same kind and amount of securities, cash or property which the holders would have received had they exercised the Series D Warrants immediately prior to such fundamental transaction.
	Series G Convertible Preferred Stock
	On July 6 and November 15, 2012, we completed a private placement, pursuant to which we sold an aggregate of 145,320 units for a purchase price of $5.00 per unit (the “Series G Purchase Price”), resulting in gross proceeds to us of $726,600 (the “Series G Private Placement”). Each unit (“Series G Unit”) consists of (i) one share of Series G Convertible Preferred Stock, $0.01 par value per share (the “Series G Preferred Stock”) convertible into 10 shares of our common stock, (subject to adjustment for stock splits, stock dividends, recapitalization, etc.) and (ii) a three-year warrant to purchase 5 shares of our common stock at a per share exercise price of $0.50 (the “Series G Warrant”). The Series G Warrants will be exercisable until the close of business on the third anniversary of the applicable closing date of the Series G Private Placement. Of the $726,600 invested in the Series G Private Placement, $31,100 was received in cash and $695,500 was from the conversion of outstanding indebtedness and accrued board of directors’ fees.
	Each share of Series G Preferred Stock will receive a cumulative dividend at the annual rate of (i) four percent (4%) on those shares of Series G Preferred Stock purchased from the Company by an individual purchaser with an aggregate investment of less than $100,000, (ii) six percent (6%) on those shares of Series G Preferred Stock purchased from the Company by an individual purchaser with an aggregate investment of at least $100,000 but less than $250,000, and (iii) twelve percent (12%) on those shares of Series G Preferred Stock purchased from the Company by an individual purchaser with an aggregate investment of at least $250,000. Dividends accruing on the Series G Preferred Stock shall accrue from day to day until, and shall be paid within fifteen (15) days of, the first anniversary of, the original issue date of the Series G Preferred Stock; provided, however, if any shares of the Company’s Series E Preferred Stock are outstanding at such time, payment of the accrued dividends on the Series G Preferred Stock shall be deferred until no such shares of Series E Convertible Preferred Stock remain outstanding. The Company may pay accrued dividends on the Series G Preferred Stock in cash or in shares of its common stock equal to the volume weighted average price of the common stock as reported by the OTC QB Market for the ten (10) trading days immediately preceding the Series G’s first anniversary.
	At the election of the Company and upon required advanced notice, each share of Series G Preferred Stock will automatically be converted into shares of  common stock at the Conversion Ratio then in effect: (i) if, after 6 months from the original issuance date of the Series G Preferred Stock, the  common stock trades on the OTC QB Market (or other primary trading market or exchange on which the  common stock is then traded) at a price equal to at least $0.75, for 7 out of 10 consecutive trading days with average daily trading volume of at least 10,000 shares, (ii) on or after the first anniversary of the original issuance date of the Series G Preferred Stock or (iii) upon completion of a firm-commitment underwritten registered public offering by the Company at a per share price equal to at least $0.75, with aggregate gross proceeds to the Company of not less than $2.5 million. Unless waived under certain circumstances by the holder of the Series G Preferred Stock, such holder’s Series G Preferred Stock may not be converted if upon such conversion the holder’s beneficial ownership would exceed certain thresholds.
	The holders of Series G Preferred Stock are not entitled to vote on any matters presented to the stockholders of the Company for their action or consideration at any meeting of stockholders of the Company (or by written consent of stockholders in lieu of meeting), except as required by law.
	Series G Warrants
	The Series G Warrants issued in the Series G Private Placement have an exercise price equal to $0.50 per share, with a term expiring on July 6, 2015. The Series G Warrants also permit the holder to conduct a “cashless exercise” at any time the holder of the Series G Warrant is an affiliate of the Company. The exercise price and/or number of shares issuable upon exercise of the Series G Warrants will be subject to adjustment for stock dividends, stock splits or similar capital reorganizations, as set forth in the Series G Warrants.
	Subject to the terms and conditions of the Series G Warrants, at any time commencing six months from the closing date the Company has the right to call for cancellation of the Series G Warrants if the volume weighted average price of its  common stock on the OTC QB Market (or other primary trading market or exchange on which our  common stock is then traded) equals or exceeds three times the per share exercise price of the Warrants for either (i) 10 consecutive trading days or (ii) 15 out of 25 consecutive trading days.
	In connection with our sale of Series G Units, we agreed that for each share of Series G Preferred Stock purchased by an investor, the exercise price of one warrant to purchase one share of common stock, previously issued to the investor in prior offerings by the Company to purchase common stock of the Company held of record by such investor, shall be reduced to $0.60 per share and will remain at such reduced exercise price until the expiration date of the warrants.
	In connection with the sale of Series G Units, we treated the reduction in exercise price as a warrant amendment and calculated the fair value of 1,495,022 warrants with the reduced exercise price of $0.60, as described above, using the Black-Scholes model with the below assumptions. The Company has determined that the fair value of the amended warrants increased as compared with the fair value of the original warrants immediately prior to amendment.
	Series H Convertible Preferred Stock
	On December 28, 2012 the Company amended the Articles of Incorporation to authorize 10,000 shares of Series H Convertible Preferred Stock.  On January 4, 2013, the Company reported that it had entered into a securities purchase and exchange agreement with an investor, pursuant to which the Company agreed to exchange 1,000,000 shares of the Company’s common stock, par value $0.01 per share of common stock held by the investor for an aggregate of 10,000 shares of a newly created series of preferred stock, designated Series H Convertible Preferred Stock, par value $0.01 per share (the “Series H Preferred Stock”) in a non-cash transaction. The investor originally purchased the common stock from the Company for $0.8025 per share.  The exchange ratio was 100 shares of common stock per share of Series H Preferred Stock at a stated conversion price of $0.8025 per share.
	Series H2 Convertible Preferred Stock
	On December 23, 2014 the Company amended the Articles of Incorporation to authorize 21 shares of Series H2 Convertible Preferred Stock.  On December 23, 2014, the Company reported that it had entered into a securities purchase and exchange agreement with an investor, pursuant to which the Company agreed to exchange 2,100,000 shares of the Company’s common stock, par value $0.01 per share of common stock held by the investor for an aggregate of 21 shares of a newly created series of preferred stock, designated Series H2 Convertible Preferred Stock, par value $0.01 per share (the “Series H2 Preferred Stock”) in a non-cash transaction. The investor originally acquired the common stock from the Company for $0.25 per share in the warrant reset transaction on December 23, 2014.  The exchange ratio was 100,000 shares of common stock per share of Series H2 Preferred Stock at a stated conversion price of $0.25 per share.
	Series J Convertible Preferred Stock
	On February 6, March 28 and May 20, 2013, the Company entered into a Securities Purchase with various individuals pursuant to which the Company sold an aggregate of 5,087.5 units for a purchase price of $400.00 per unit (the “Purchase Price”), or an aggregate Purchase Price of $2,034,700.  Each unit purchased in the initial tranche consists of (i) one share of a newly created series of preferred stock, designated Series J Convertible Preferred Stock, par value $0.01 per share (the “Series J Convertible Preferred Stock”), convertible into 1,000 shares of the Company’s common stock, par value $0.01 per share and (ii) a warrant to purchase 1,000 shares of common stock at an exercise price equal to $0.40 per share. The warrants expire three years from the issuance date. Of the $2,034,700 invested in the Private Placement, $921,000 was received in cash and $1,113,700 was from the conversion of outstanding indebtedness, interest and accrued board of directors’ fees.  The Company incurred $24,405 of legal fees in conjunction with this private placement. The purchasers in the initial tranche of the private placement consisted of certain existing and new investors in the Company as well as all of the members of the Company’s Board of Directors.
	From the date of issuance of any shares of Series J Convertible Preferred Stock and until the earlier of the first anniversary of such date, the voluntary conversion of any shares of Series J Convertible Preferred Stock, or the date of any mandatory conversion (solely under the Company’s control based upon certain triggering events) of the Series J Convertible Preferred Stock, dividends will accrue on each share of Series J Convertible Preferred Stock at an annual rate of (i) four percent (4%) of the Purchase Price on those shares of Series J Convertible Preferred Stock purchased from the Company pursuant to the Securities Purchase Agreement by an individual purchaser who purchased from the Company shares of Series J Convertible Preferred Stock with an aggregate Purchase Price of less than $250,000, and (ii) six percent (6%) of the Purchase Price on those shares of Series J Convertible Preferred Stock purchased from the Company pursuant to the Securities Purchase Agreement by an individual purchaser who purchased shares of Series J Convertible Preferred Stock with an aggregate purchase price of at least $250,000.  Dividends accruing on the Series J Convertible Preferred Stock shall accrue from day to day until the earlier of the first anniversary of the date of issuance of such shares of Series J Convertible Stock, the voluntary conversion of any shares of Series J Convertible Preferred Stock, or the date of any mandatory conversion of the Series J Convertible Preferred Stock, and shall be paid, as applicable, within fifteen (15) days of the first anniversary of the original issue date of the Series J Convertible Preferred Stock, within five (5) days of the voluntary conversion of shares of the Series J Convertible Preferred Stock, or within five (5) days of the mandatory conversion of shares of the Series J Convertible Preferred Stock. The Company may pay accrued dividends on the Series J Convertible Preferred Stock in cash or, in the sole discretion of the Board of Directors of the Company, in shares of its common stock in accordance with a specified formula.
	Each share of Series J Convertible Preferred Stock is convertible into 1,000 shares of common stock at the option of the holder on or after the six-month anniversary of the issuance of such share, subject to adjustment for stock splits, stock dividends, recapitalizations and similar transactions (the “Conversion Ratio”). Unless waived under certain circumstances by the holder of Series J Convertible Preferred Stock, such holder’s shares of Series J Convertible Preferred Stock may not be converted if upon such conversion the holder’s beneficial ownership would exceed certain thresholds.
	At the election of the Company and upon required advance notice, each share of Series J Convertible Preferred Stock will automatically be converted into shares of common stock at the Conversion Ratio then in effect:  (i) on or after the six-month anniversary of the original issuance date of the Series J Convertible Preferred Stock, the common stock trades on the OTC QB Market (or other primary trading market or exchange on which the common stock is then traded) at a price per share equal to at least $0.80 for 7 out of 10 consecutive trading days with average daily trading volume of at least 50,000 shares, (ii) on the first anniversary of the original issuance date of the Series J Convertible Preferred Stock or (iii) within three days of the completion of a firm-commitment underwritten registered public offering by the Company at a per share price equal to at least $0.80, with aggregate gross proceeds to the Company of not less than $2.5 million.  Unless waived under certain circumstances by the holder of the Series J Convertible Preferred Stock, such holder’s Series J Convertible Preferred Stock may not be converted if upon such conversion the holder’s beneficial ownership would exceed certain thresholds.
	The proceeds from the sale of each Series J Unit were allocated between the Series J Convertible Preferred Stock and the Series J Warrants based on the relative fair value method.  The estimated fair value of the Series J Warrants was determined using a Black Scholes formula, resulting in an allocation of the gross proceeds of $885,309 to the total warrants issued.  The allocation of the gross proceeds to the Series J Convertible Preferred Stock was $1,124,986, net of $24,405 in legal costs.  In accordance with the provisions of ASC 470-20, an additional adjustment between Additional Paid in Capital and Accumulated Deficit of $651,182 was recorded to reflect an implicit non-cash dividend related to the allocation of proceeds between the stock and warrants issued. The $651,182 represents the value of the adjustment to additional paid in capital related to the beneficial conversion feature of the Series J Convertible Preferred Stock.  The value adjustment was calculated by subtracting the fair market value of the underlying common stock on February 6, March 28 and May 20, 2013 issuable upon conversion of the Series J Convertible Preferred Stock from the fair market value of the Series J Convertible Preferred Stock as determined when the Company performed a fair market value allocation of the proceeds to the Series J Convertible Preferred Stock and warrants.
	In connection with the Series J warrants, we calculated the fair value of the warrants received as described above using the Black- Scholes formula with the below assumptions:
	Assumptions		Series J warrants February 6, 2013			Series J warrants March 28, 2013			Series J warrants May 20, 2013
	Contractual life (in months)			36			36			36
	Expected volatility			141.8			144.3			147
	Risk-free interest rate			0.39	%		0.36	%		0.36	%
	Exercise price		$	0.4		$	0.4		$	0.4
	Fair value per warrant		$	0.36		$	0.26		$	0.3
	The holders of Series J Convertible Preferred Stock are not entitled to vote on any matters presented to the stockholders of the Company for their action or consideration at any meeting of stockholders of the Company (or by written consent of stockholders in lieu of meeting), except as required by law.
	Series J Warrants
	The Warrants issued in the Private Placement have an exercise price equal to $0.40 per share, with a term expiring three years from the issuance date.  The Warrants also permit the holder to conduct a “cashless exercise” at any time the holder of the Warrant is an affiliate of the Company.  The exercise price and/or number of shares issuable upon exercise of the Warrants will be subject to adjustment for stock dividends, stock splits or similar capital reorganizations, as set forth in the Warrant agreement.
	Subject to the terms and conditions of the Warrants, at any time commencing six months from the closing date of the sale of Units under the Securities Purchase Agreement the Company has the right to call the Warrants for cancellation if the volume weighted average price of its common stock on the OTC QB Market (or other primary trading market or exchange on which the common stock is then traded) equals or exceeds three times the per share exercise price of the Warrants for either (i) 10 consecutive trading days or (ii) 15 out of 25 consecutive trading days.
	Registration Rights Agreement
	In connection with the Private Placement, the Company has agreed that, if, at any time after February 1, 2014, the Company files a Registration Statement relating to an offering of equity securities of the Company (the “Registration Statement”), subject to certain exceptions, including a Registration Statement relating solely to an offering or sale of securities having an aggregate public offering price of less than $5,000,000, the Company shall include in the Registration Statement the resale of the shares of common stock underlying the Warrants.  Shares of common stock issued upon conversion of Series J Convertible Preferred Stock or in payment of the dividend on the Series J Convertible Preferred Stock will not be registered and will not be subject to registration rights.  This right is subject to customary conditions and procedures.
	Series K Convertible Preferred Stock
	On December 12, 2013, the Company entered into a Securities Purchase with various individuals pursuant to which the Company sold an aggregate of 4,000 units for a purchase price of $250.00 per unit (the “Purchase Price”), for an aggregate Purchase Price of $1,000,000.  Each unit purchased in the initial tranche consists of (i) one share of a newly created series of preferred stock, designated Series K Convertible Preferred Stock, par value $0.01 per share (the “Series K Convertible Preferred Stock”), convertible into 1,000 shares of the Company’s common stock, par value $0.01 per share and (ii) a warrant to purchase 500 shares of common stock at an exercise price equal to $0.3125 per share. The warrants expire three years from the issuance date. Of the $1,000,000 invested in the Private Placement, $572,044 was received in cash and $427,956 was from the conversion of outstanding indebtedness and interest. The Company incurred $43,334 of fees in conjunction with this private placement. The purchasers in the initial tranche of the private placement consisted of certain existing and new investors in the Company as well as all of the members of the Company’s Board of Directors.
	From the date of issuance of any shares of Series K Convertible Preferred Stock and until the earlier of the first anniversary of such date, the voluntary conversion of any shares of Series K Convertible Preferred Stock, or the date of any mandatory conversion (solely under the Company’s control based upon certain triggering events) of the Series K Convertible Preferred Stock, dividends will accrue on each share of Series K Convertible Preferred Stock at an annual rate of (i) four percent (4%) of the Purchase Price on those shares of Series K Convertible Preferred Stock purchased from the Company pursuant to the Securities Purchase Agreement by an individual purchaser who purchased from the Company shares of Series K Convertible Preferred Stock with an aggregate Purchase Price of less than $100,000, and (ii) six percent (6%) of the Purchase Price on those shares of Series K Convertible Preferred Stock purchased from the Company pursuant to the Securities Purchase Agreement by an individual purchaser who purchased shares of Series K Convertible Preferred Stock with an aggregate purchase price of at least $100,000.  Dividends accruing on the Series K Convertible Preferred Stock shall accrue from day to day until the earlier of the first anniversary of the date of issuance of such shares of Series K Convertible Stock, the voluntary conversion of any shares of Series K Convertible Preferred Stock, or the date of any mandatory conversion of the Series K Convertible Preferred Stock, and shall be paid, as applicable, within fifteen (15) days of the first anniversary of the original issue date of the Series K Convertible Preferred Stock, within five (5) days of the voluntary conversion of shares of the Series K Convertible Preferred Stock, or within five (5) days of the mandatory conversion of shares of the Series K Convertible Preferred Stock. The Company may pay accrued dividends on the Series K Convertible Preferred Stock in cash or, in the sole discretion of the Board of Directors of the Company, in shares of its common stock in accordance with a specified formula.
	Each share of Series K Convertible Preferred Stock is convertible into 1,000 shares of common stock at the option of the holder on or after the six-month anniversary of the issuance of such share, subject to adjustment for stock splits, stock dividends, recapitalizations and similar transactions (the “Conversion Ratio”). Unless waived under certain circumstances by the holder of Series K Convertible Preferred Stock, such holder’s shares of Series K Convertible Preferred Stock may not be converted if upon such conversion the holder’s beneficial ownership would exceed certain thresholds.
At the election of the Company and upon required advance notice, each share of Series K Convertible Preferred Stock will automatically be converted into shares of common stock at the Conversion Ratio then in effect:  (i) on or after the six-month anniversary of the original issuance date of the Series K Convertible Preferred Stock, the common stock trades on the OTC QB Market (or other primary trading market or exchange on which the common stock is then traded) at a price per share equal to at least $0.80 for 7 out of 10 consecutive trading days with average daily trading volume of at least 50,000 shares, (ii) on the first anniversary of the original issuance date of the Series K Convertible Preferred Stock or (iii) within three days of the completion of a firm-commitment underwritten registered public offering by the Company at a per share price equal to at least $0.80, with aggregate gross proceeds to the Company of not less than $2.5 million.  Unless waived under certain circumstances by the holder of the Series K Convertible Preferred Stock, such holder’s Series K Convertible Preferred Stock may not be converted if upon such conversion the holder’s beneficial ownership would exceed certain thresholds.
The proceeds from the sale of each Series K Unit were allocated between the Series K Convertible Preferred Stock and the Series K Warrants based on the relative fair value method.  The estimated fair value of the Series K Warrants was determined using a Black-Scholes formula, resulting in an allocation of the gross proceeds of $271,422 to the total warrants issued.  The allocation of the gross proceeds to the Series K Convertible Preferred Stock was $685,245, net of $43,334 in fees.  In accordance with the provisions of ASC 470-20, an additional adjustment between Additional Paid in Capital and Accumulated Deficit of $351,421 was recorded to reflect an implicit non-cash dividend related to the allocation of proceeds between the stock and warrants issued. The $351,421 represents the value of the adjustment to additional paid in capital related to the beneficial conversion feature of the Series K Convertible Preferred Stock.  The value adjustment was calculated by subtracting the fair market value of the underlying common stock on December 12, 2013 issuable upon conversion of the Series K Convertible Preferred Stock from the fair market value of the Series K Convertible Preferred Stock as determined when the Company performed a fair market value allocation of the proceeds to the Series K Convertible Preferred Stock and warrants.
On January 29, 2014, the Company entered into a Securities Purchase Agreement with various accredited investors, pursuant to which the Company sold an aggregate of 4,875 units for a purchase price of $250.00 per unit or an aggregate Purchase Price of $1,218,750.  This was the second tranche of a $1.5 million private placement previously disclosed by the Company in its Current Report on Form 8-K filed with the Securities and Exchange Commission on December 12, 2013, which is incorporated by reference herein. The Purchasers in the second tranche of the Private Placement consisted of certain existing and new investors in the Company, as well as all of the members of the Company’s Board of Directors.
Each unit purchased in the second tranche consists of (i) one share of Series K Convertible Preferred Stock, par value $0.01 per share, convertible into 1,000 shares of the Company’s common stock, par value $0.01 per share and (ii) a warrant to purchase 500 shares of common stock at an exercise price equal to $0.3125 per share, with a term expiring on January 29, 2017.
On February 28, 2014, the Company entered into a Securities Purchase Agreement with various accredited investors, pursuant to which the Company sold an aggregate of 1,854 units for a purchase price of $340.00 per unit or an aggregate Purchase Price of $630,360.  This was the third tranche of a $1.5 million private placement previously disclosed by the Company in its Current Report on Form 8-K filed with the Securities and Exchange Commission on December 12, 2013, which is incorporated by reference herein. The Purchasers in the third tranche of the Private Placement consisted of certain existing and new investors in the Company.
Each unit purchased in the third tranche consists of (i) one share of Series K Convertible Preferred Stock, par value $0.01 per share convertible into 1,000 shares of the Company’s common stock, par value $0.01 per share and (ii) a warrant to purchase 500 shares of common stock at an exercise price equal to $0.425 per share, with a term expiring on February 28, 2017.
On June 30, 2014, the Company entered into a Securities Purchase Agreement with various accredited investors, pursuant to which the Company sold an aggregate of 734 units for a purchase price of $300.00 per unit or an aggregate Purchase Price of $220,000.  This was the fourth tranche of a $1.5 million private placement previously disclosed by the Company in its Current Report on Form 8-K filed with the Securities and Exchange Commission on December 12, 2013, which is incorporated by reference herein. The Purchasers in the fourth tranche of the Private Placement consisted of certain existing and new investors in the Company.
Each unit purchased in the fourth tranche consists of (i) one share of Series K Convertible Preferred Stock, par value $0.01 per share convertible into 1,000 shares of the Company’s common stock, par value $0.01 per share and (ii) a warrant to purchase 500 shares of common stock at an exercise price equal to $0.375 per share, with a term expiring on June 30, 2017.
On November 12, 2014, the Company entered into a Securities Purchase Agreement with various accredited investors, pursuant to which the Company sold an aggregate of 1,052 units for a purchase price of $250.00 per unit or an aggregate Purchase Price of $263,000.  This was the fifth tranche of a $1.5 million private placement previously disclosed by the Company in its Current Report on Form 8-K filed with the Securities and Exchange Commission on December 12, 2013, which is incorporated by reference herein. The Purchasers in the fourth tranche of the Private Placement consisted of certain existing and new investors in the Company.
Each unit purchased in the fifth tranche consists of (i) one share of Series K Convertible Preferred Stock, par value $0.01 per share convertible into 1,000 shares of the Company’s common stock, par value $0.01 per share and (ii) a warrant to purchase 500 shares of common stock at an exercise price equal to $0.3125 per share, with a term expiring on November 12, 2017.
The Private Placement was originally expected to raise $1.5 million and close on or before January 31, 2014.  On January 29, 2014, the Company’s Board of Directors voted to increase the subscription amount of the Private Placement by $718,750.  The Board of Directors also voted to extend the Private Placement until February 28, 2014. On February 28, 2014 the Company’s Board of Directors voted to increase the subscription amount once again to a total of $3.5 million and extended the closing to April 4, 2014. On April 13, 2014 the Company’s Board of Directors voted to increase the subscription amount by $1 million, to a total of $4.5 million, and extended the closing to May 31, 2014.  On July 7, 2014 the Company’s Board of Directors voted to extend the closing to August 15, 2014. Together with the initial tranche of $1,000,000 that closed on December 12, 2013, the second tranche of $1,218,750 that closed January 29, 2014, the third tranche of $630,360 that closed February 28, 2014, the fourth tranche of $220,000 that closed June 30, 2014, and the fifth tranche of $263,000 that closed November 12, 2014,the total consideration received by the Company in the Private Placement is $3,332,110, which is comprised of $2,511,404 in cash and $820,706 from the conversion of outstanding indebtedness and Board of Director fees.  The placement was closed after the November 12, 2014 round.
On September 22, 2014 the Company issued 64,000 shares of common stock for the conversion of 64 shares of Series K Preferred Convertible Stock.
In connection with the Series K Warrants, we calculated the fair value of the warrants received as described above using the Black- Scholes formula with the below assumptions:
Assumptions		Series K Warrants December 12, 2013			Series K Warrants			Series K Warrants			Series K Warrants			Series K Warrants
					January 29,			28-Feb			June 30,			November 12,
					2014			2014			2014			2014
Contractual life (in months)			36			36			36			36			36
Expected volatility			136.1			152.4			152.7			153.9			153.9
Risk-free interest rate			0.39	%		0.39	%		0.39	%		0.9	%		0.9	%
Exercise price		$	0.3125		$	0.3125		$	0.425		$	0.375		$	0.3125
Fair value per warrant		$	0.2		$	0.3		$	0.37		$	0.29		$	0.23
The holders of Series K Convertible Preferred Stock are not entitled to vote on any matters presented to the stockholders of the Company for their action or consideration at any meeting of stockholders of the Company (or by written consent of stockholders in lieu of meeting), except as required by law.
Series K Warrants
The warrants issued in the Private Placement have an exercise price equal to $0.3125 per share, for the December 12, 2013 and January 29, 2014 warrants, $0.425 per share for the February 28, 2014 warrants, $0.375 per share for the June 30, 2014 warrants and $0.3125 per share for the November 12, 2014 warrants, with a term expiring three years from the issuance date.  The warrants also permit the holder to conduct a “cashless exercise” at any time the holder of the warrant is an affiliate of the Company.  The exercise price and/or number of shares issuable upon exercise of the warrants will be subject to adjustment for stock dividends, stock splits or similar capital reorganizations, as set forth in the warrant agreement.
Subject to the terms and conditions of the warrants, at any time commencing six months from the closing date of the sale of Units under the Securities Purchase Agreement the Company has the right to call the warrants for cancellation if the volume weighted average price of its common stock on the OTC QB Market (or other primary trading market or exchange on which the common stock is then traded) equals or exceeds three times the per share exercise price of the warrants for either (i) 10 consecutive trading days or (ii) 15 out of 25 consecutive trading days.
Registration Rights Agreement
In connection with the Private Placement, the Company has agreed that, if, at any time after February 1, 2014, the Company files a Registration Statement relating to an offering of equity securities of the Company (the “Registration Statement”), subject to certain exceptions, including a Registration Statement relating solely to an offering or sale of securities having an aggregate public offering price of less than $5,000,000, the Company shall include in the Registration Statement the resale of the shares of common stock underlying the warrants.  Shares of common stock issued upon conversion of Series K Convertible Preferred Stock or in payment of the dividend on the Series K Convertible Preferred Stock will not be registered and will not be subject to registration rights.  This right is subject to customary conditions and procedures.
Common Stock
Shareholders Purchase Rights Plan
On March 3, 2003, our Board of Directors adopted a shareholder purchase rights plan (“the Rights Plan”) and declared a distribution of one Right for each outstanding share of our  common stock to shareholders of record at the close of business on March 21, 2003 (the “Rights”). Initially, the Rights will trade automatically with the common stock and separate Right Certificates will not be issued. The Rights Plan is designed to deter coercive or unfair takeover tactics and to ensure that all of our shareholders receive fair and equal treatment in the event of an unsolicited attempt to acquire the Company. The Rights Plan was not adopted in response to any effort to acquire the Company and the Board is not aware of any such effort. The Rights will expire on February 27, 2013 unless earlier redeemed or exchanged. Each Right entitles the registered holder, subject to the terms of a Rights Agreement, to purchase from the Company one one-thousandth of a share of the Company’s Series A Junior Participating Preferred Stock at a purchase price of $45.00 per one one-thousandth of a share, subject to adjustment. In general, the Rights will not be exercisable until a subsequent distribution date which will only occur if a person or group acquires beneficial ownership of 15% or more of our common stock or announces a tender or exchange offer that would result in such person or group owning 15% or more of the common stock. With respect to any person or group who currently beneficially owns 15% or more of our common stock, the Rights will not become exercisable unless and until such person or group acquires beneficial ownership of additional shares of common stock.
Subject to certain limited exceptions, if a person or group acquires beneficial ownership of 15% or more of our outstanding  common stock or if a current 15% beneficial owner acquires additional shares of  common stock, each holder of a Right (other than the 15% holder whose Rights become void once such holder reaches the 15% threshold) will thereafter have a right to purchase, upon payment of the purchase price of the Right, that number of shares of our  common stock which at the time of such transaction will have a market value equal to two times the purchase price of the Right In the event that, at any time after a person or group acquires 15% or more of our  common stock, we are acquired in a merger or other business combination transaction or 50% or more of its consolidated assets or earning power are sold, each holder of a Right will thereafter have the right to purchase, upon payment of the purchase price of the Right, that number of shares of  common stock of the acquiring company which at the time of such transaction will have a market value of two times the purchase price of the Right.
Our Board of Directors may exchange the Rights (other than Rights owned by such person or group which have become void), in whole or in part, at an exchange ratio of one share of common stock per Right (subject to adjustment). At any time prior to the time any person or group acquires 15% or more of our common stock, the Board of Directors may redeem the Rights in whole, but not in part, at a price of $0.001 per Right.
Stock Options and Warrants
Our stockholders approved our amended 2005 Equity Incentive Plan (the “Plan”) pursuant to which an aggregate of 1,800,000 shares of our  common stock were reserved for issuance upon exercise of stock options or other equity awards made under the Plan. Under the Plan, we may award stock options, shares of  common stock, and other equity interests in the Company to employees, officers, directors, consultants, and advisors, and to any other persons the Board of Directors deems appropriate. As of December 31, 2014, options to acquire 1,720,750 shares were outstanding under the Plan with 79,250 shares available for future grant under the Plan.
As of December 31, 2014, options to acquire 10,000 shares are outstanding under the 1999 Non-qualified Stock Option Plan. No additional options may be granted under the 1999 Non-qualified Stock Option Plan.
On December 12, 2013 at the Company’s special meeting the shareholders approved the 2013 Equity Incentive Plan (the “2013 Plan”) pursuant to which 3,000,000 shares of our common stock were reserved for issuance upon exercise of stock options or other equity awards under the 2013 Plan. Under the Plan, we may award stock options, shares of  common stock, and other equity interests in the Company to employees, officers, directors, consultants, and advisors, and to any other persons the Board of Directors deems appropriate. As of December 31, 2014 1,675,500 options have been granted under the 2013 Plan.
All of the outstanding options had an exercise price that was above the Company’s common stock share price on December 31, 2014.
The following tables summarize information concerning options and warrants outstanding and exercisable:
		Stock Options						Warrants
		Weighted						Weighted
		Average price						Average price						Total
		Shares			per share			Shares			per share			Shares			Exercisable
Balance outstanding, January 1, 2013			1,605,750		$	0.8			6,687,099		$	0.81			8,292,849			7,989,331
Granted			363,500			0.41			8,346,228			0.37			8,709,728
Exercised			-			-			-			-			-
Expired			(10,000	)		1			(21,000	)		2.38			(31,000	)
Forfeited			(187,542	)		0.85			-			-			(187,542	)
Balance outstanding, December 31, 2013			1,771,708		$	0.71			15,012,327		$	0.57			16,784,035			16,611,528
Granted			1,675,500			0.3			8,903,000			0.38			10,578,500
Exercised			-			-			(4,208,658	)		0.25			(4,208,658	)
Expired			(10,000	)		1			(524,468	)		0.74			(534,468	)
Forfeited			(30,985	)		0.71			-			-			(30,958	)
Balance outstanding, December 31, 2014			3,406,250		$	0.51			19,182,201		$	0.49			22,588,451			20,858,111
The weighted average grant date fair value of options issued was $0.25 for the year ending December 31, 2014.
			Options Outstanding									Options Exercisable
						Weighted Average									Weighted Average
Range of Exercise Prices			Number of Options			Remaining Contractual Life (Years)			Exercise Price			Number of Options			Remaining Contractual Life (Years)			Exercise Price
$0.30-$0.39				1,675,500			9.7		$	0.3			-			-		$	-
0.40-0.49				311,000			8.4			0.4			311,000			8.4			0.4
0.50-0.59				251,250			7.6			0.5			251,250			7.6			0.5
0.60-0.69				467,500			5			0.6			433,283			4.8			0.6
0.70-1.25				701,000			2.2			1			680,377			2.1			1
$0.30-$1.25				3,406,250			5.1		$	0.51			1,675,910			4.8		$	0.72
There was $323,811 of total unrecognized compensation cost, net of estimated forfeitures, related to non-vested stock options granted as of December 31, 2014. This cost is expected to be recognized over a period of 2.1 years, and will be adjusted for any future changes in estimated forfeitures.
Common Stock Issuances
On February 1, 2013, we issued 100,000 shares of restricted common stock to an investor relations firm in payment of services to be rendered over eight months. We recorded $40,000 for this issuance of which will be amortized over the eight months. On March 18, 2013, we issued 200,000 shares of restricted common stock to an investor relations firm for payment of services to be rendered over eight months. We recorded $80,000 for this issuance as expense. On August 1, 2013, we issued 200,000 shares of restricted common stock to an investor relations firm for payment of services to be rendered over six months. We recorded $80,000 for this issuance and recognized $66,087 as expense in 2013 with $13,913 to be expensed in 2014. On September 1, 2013, we issued 200,000 shares of restricted common stock to an investor relations firm for payment of services to be rendered over three months. We recorded $80,000 for this issuance which was recorded as expense in 2013. On September 10, 2013, we issued 100,000 shares of restricted common stock to an investor relations firm for payment of services to be rendered over four months. We recorded $40,000 for this issuance and recognized expense of $36,721 in 2013 with $3,279 to be expensed in 2014.  On December 23, 2014 we issued 75,000 shares of restricted common stock to a lender in connection with the sale of debentures.  We recognized $17,250 as deferred financing costs that will be recognized over the life of the note. We valued the above stock issuances using the greater of the estimated fair value of the services received or the Company’s stock price on date of issuance.
On August 1, 2013, we issued 200,000 shares of restricted common stock to an investor relations firm for payment of services to be rendered over six months. We recorded $80,000 for this issuance and recognized $66,087 as expense in 2013 and $13,913 was expensed in the period ended March 31, 2014. On September 10, 2013, we issued 100,000 shares of restricted common stock to an investor relations firm for payment of services to be rendered over four months. We recorded $40,000 for this issuance and recognized expense of $36,721 in 2013 with $3,279 expensed in the period ended March 31, 2014.  On December 23, 2013 we issued 75,000 shares of restricted common stock to a lender in connection with the sale of debentures.  We recognized $17,250 as deferred financing costs that will be recognized over the life of the note.  We valued the above stock issuances using the greater of the estimated fair value of the services received or the Company’s stock price on date of issuance.
On February 10, 2014 a lender, with the prior approval of the Company, chose to convert $37,500 of their outstanding note balance into 150,000 shares of the Company’s common stock.
On June 23, 2014 a lender, with the prior approval of the Company, chose to convert $50,000 of their outstanding note balance into 200,000 shares of the Company’s common stock.
In March and April 2014, a Series D warrant holder exercised warrants to purchase 596,658 shares of common stock resulting in net proceeds to the Company of $149,164.
In April 2014 we issued 733,169 shares of common stock to holders of Series G Convertible Preferred Stock for the conversion of 58,750 shares of preferred and $58,267 of accrued and unpaid dividends on the Series G Convertible Preferred Stock. We also issued 92,500 shares of common stock to holders of Series J Convertible Preferred Stock for the conversion of 92.5 shares of Series J Convertible Preferred Stock.
In July 2014 we issued 1,517,466 shares of common stock to holders of Series J Convertible Preferred Stock for the conversion of 1,449 shares of preferred and $24,648 of accrued and unpaid dividends on the Series J Convertible Preferred Stock. On August 13. 2014 we issued 200,000 shares of common stock to an investor relations firm for services. The Company recorded $52,000 as expense related to these services.   On September 9, 2014 we issued 75,000 shares of commons stock to a lender as a fee for a $175,000 loan.  On September 18, 2014 we issued 75,000 shares of common stock to and investor relations firm as payment for services provided to the Company in 2014. The Company recorded $44,250 in expense related to this transaction.
On September 22, 2014 the Company issued 64,000 shares of common stock for the conversion of 64 shares of Series K Preferred Convertible Stock.  On December 22, 2014 the Company issued 1,035,000 shares of common stock for the conversion of 1,035 shares of Series K Preferred Convertible Stock.
In December we issued a total of 160,000 shares of common stock to a lender in exchange for $49,000 of outstanding loans and fees.  We also issued a total of 238,830 shares of common stock to four investor relations firms for services provided.
On December 23, 2014 we issued 3,612,000 shares of common stock for the exercise of warrants in a warrant reset agreement.  2,100,000 of these common stock shares were converted to Series H2 Convertible Preferred Stock.
Warrant Reset Agreement
On December 23, 2014, The Company closed a series of Warrant Reset Agreements (“Warrant Reset Agreements”) with 30 warrant holders (the “Warrant Holders”) in order to re-price their Common Stock Purchase Warrants (the “Warrants”). In consideration for the Warrant Holder exercising their outstanding Warrants by or before December 23, 2014, the Company agreed to reduce the exercise price to $0.25 per warrant share. In addition, for each warrant exercised (the “Exercised Warrant”), the Warrant Holder received a New Warrant (the “New Warrant”) to purchase that same number of Warrant Shares as exercised, at an exercise price of $0.40 per share. If the Exercised Warrant terminated on or before December 31, 2015, the date of termination of the New Warrant was December 31, 2015. If the date of termination of the Exercised Warrant was after December 31, 2015, the date of termination of the New Warrant was the same as that of the Exercised Warrant.
As a result of the Warrant Reset Agreements, the Company received $903,000 from the exercise of warrants and incurred $40,481 in fees. The Company has issued New Warrants for 3,612,000 warrant shares, and has requested its transfer agent to issue 3,612,000 shares of restricted Common Stock (the “Exercised Warrant Shares”) to the investors. Neither the Exercised Warrant Shares nor the shares underlying the New Warrants will be registered for sale pursuant to a registration statement.
The Company estimated the fair value of the New Warrants issued in the transaction using the Black-Scholes pricing model. $163,654 of the net proceeds was allocated to the New Warrants.
Warrant Derivative Liability
The Series D Warrants issued in connection with the registered direct offering of Series D Convertible Preferred are measured at fair value and liability-classified because the Series D Warrants contain “down-round protection” and therefore, do not meet the scope exception for treatment as a derivative under ASC 815, Derivatives and Hedging, (“ASC 815”). Since “down-round protection” is not an input into the calculation of the fair value of the warrants, the warrants cannot be considered indexed to the Company’s own stock which is a requirement for the scope exception as outlined under ASC 815. The estimated fair value of the warrants was determined using the binomial model, resulting in an allocation of the gross proceeds $283,725 to the warrants issued in the Series D registered direct offering. The fair value will be affected by changes in inputs to that model including our stock price, expected stock price volatility, the contractual term, and the risk-free interest rate. We will continue to classify the fair value of the warrants as a liability until the warrants are exercised, expire or are amended in a way that would no longer require these warrants to be classified as a liability, whichever comes first. The down-round protection for the Series D Warrants survives for the life of the Series D Warrants which ends in May 2017. During the year ended December 31, 2014 a total of 596,658 warrants were exercised at an exercise price of $0.25 resulting in net proceeds to the Company of $149,165.
The assumptions for the binomial pricing model are represented in the table below for the warrants issued in the Series D private placement reflected on a per share  common stock equivalent basis.
Assumptions		10-Nov-11			Warrants revalued at December 31, 2013			Warrants revalued at December 31, 2014
Expected life (in months)			60			34			22
Expected volatility			104.5	%		154.8	%		116	%
Risk-free interest rate			0.875	%		0.78	%		0.58	%
Exercise price		$	0.81		$	0.25		$	0.25
Fair value per warrant		$	0.54		$	0.21		$	0.15
As of December 31, 2014, the value of the Series D Warrants had decreased to $159,875.
Conversion Option Liability
The Company signed seven convertible notes and has determined that conversion options are embedded in the notes and it is required to bifurcate the conversion option from the host contract under ASC 815 and account for the derivatives at fair value. The estimated fair value of the conversion options was determined using the binomial model. The fair value of the conversion options will be classified as a liability until the debt is converted by the note holders or paid back by the Company.  The fair value will be affected by changes in inputs to that model including our stock price, expected stock price volatility, the contractual term, and the risk-free interest rate.  We will continue to classify the fair value of the conversion options as a liability until the conversion options are exercised, expire or are amended in a way that would no longer require these conversion options to be classified as a liability, whichever comes first. The Company has adopted a sequencing policy that reclassifies contracts (from equity to liabilities) with the most recent inception date first.  Thus any available shares are allocated first to contracts with the most recent inception dates.
The assumptions for the binomial pricing model are disclosed in Note 2. As of December 31, 2014, the value of the Conversion Option liability was $590,341.

10_Subsequent_Events

10. Subsequent Events	12 Months Ended
	Dec. 31, 2014
Subsequent Events [Abstract]
10. Subsequent Events	We performed a review of events subsequent to the balance sheet date through the date the financial statements were issued and determined, except as disclosed herein, that there were no other such events requiring recognition or disclosure in the financial statements.
		●	From February 2, 2015 through March 30 2015 the Company signed 11 notes for convertible debt totaling $1,121,250.
		●	From January 15, 2015 through March 19, 2015 the Company signed 3 merchant debt agreements for approximately $330,000 in net proceeds.
		●	The Company repaid convertible notes along with prepayment penalties and accrued interest of $646,201.
		●	January 21, 2015, we announced we had received over $1.16 million during the previous two months from equity investments and that we planned to expand marketing, sales and operations capabilities.
		●	February 10, 2015 we announced we had received to first order for our Barozyme HT48 High Throughput System
		●	February 19, 2015 we announced we had been awarded a $1,000,000 NIH SBIR Phase II Grant to support the development of a high-throughput, automated, high pressure based DNA Shearing System
		●	March 12, 2015 we announced the release of PCT-HD "The Next Generation Protein Preparation System"

2_Summary_of_Significant_Accou1

2. Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Principles of Consolidation	The consolidated financial statements include the accounts of Pressure BioSciences, Inc., and its wholly-owned subsidiary PBI BioSeq, Inc. All intercompany accounts and transactions have been eliminated in consolidation.
Use of Estimates	To prepare our consolidated financial statements in conformity with accounting principles generally accepted in the United States of America, we are required to make significant estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. In addition, significant estimates were made in projecting future cash flows to quantify impairment of assets, deferred tax assets, the costs associated with fulfilling our warranty obligations for the instruments that we sell, and the estimates employed in our calculation of fair value of stock options awarded and derivative liabilities. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from the estimates and assumptions used.
Revenue Recognition	Revenue is recognized when realized or earned when all the following criteria have been met: persuasive evidence of an arrangement exists; delivery has occurred and risk of loss has passed to the customer; the seller’s price to the buyer is fixed or determinable; and collectability is reasonably assured.
	Our current instruments, the Barocycler NEP3229 and NEP2320, require a basic level of instrumentation expertise to set-up for initial operation. To support a favorable first experience for our customers, we send a highly trained technical representative to the customer site to install every Barocycler that we sell, lease, or rent through our domestic sales force. The installation process includes uncrating and setting up the instrument, followed by introductory user training. Product revenue related to current Barocycler instrumentation is recognized upon the completion of the installation and introductory training process of the instrumentation at the customer location, for domestic installations. Product revenue related to sales of PCT instrumentation to our foreign distributors is recognized upon shipment through a common carrier. We provide for the expected costs of warranty upon the recognition of revenue for the sales of our instrumentation. Our sales arrangements do not provide our customers with a right of return. Product revenue related to the HUB440 and our consumable products such as PULSE Tubes, MicroTubes, and application specific kits is recorded upon shipment through a common carrier. Shipping costs are included in sales and marketing expense. Any shipping costs billed to customers are recognized as revenue.
	We account for our lease agreements under the operating method. We record revenue over the life of the lease term and we record depreciation expense on a straight-line basis over the thirty-six month estimated useful life of the Barocycler instrument. The depreciation expense associated with assets under lease agreement is included in the “Cost of PCT products and services” line item in our consolidated statements of operations. Many of our lease and rental agreements allow the lessee to purchase the instrument at any point during the term of the agreement with partial or full credit for payments previously made. We pay all maintenance costs associated with the instrument during the term of the leases.
	Revenue from government grants is recorded when expenses are incurred under the grant in accordance with the terms of the grant award.
	Revenue from service contracts is recorded ratably over the length of the contract.
	Our transactions sometimes involve multiple elements (i.e., products and services). Revenue under multiple element arrangements is recognized in accordance with FASB ASC 605-25 Multiple-Element Arrangements (“ASC 605”). When vendor specific objective evidence or third party evidence of selling price for deliverables in an arrangement cannot be determined, the Company develops a best estimate of the selling price to separate deliverables and allocates arrangement consideration using the relative selling price method. If an arrangement includes undelivered elements that are not essential to the functionality of the delivered elements, we defer the fair value of the undelivered elements to such time as they are delivered. Fair value is determined based upon the price charged when the element is sold separately. If there is not sufficient evidence of the fair value of the undelivered elements the Company uses its best estimate of the value of those items and recognizes revenues based on the relative values of the delivered and undelivered items. We provide certain customers with extended service contracts with revenue recognized ratably over the life of the contract.
Cash and Cash Equivalents	Our policy is to invest available cash in short-term, investment grade interest-bearing obligations, including money market funds, and bank and corporate debt instruments. Securities purchased with initial maturities of three months or less are valued at cost plus accrued interest, which approximates fair value, and are classified as cash equivalents.
Research and Development	Research and development costs, which are comprised of costs incurred in performing research and development activities including wages and associated employee benefits, facilities, consumable products and overhead costs that are expensed as incurred. In support of our research and development activities we utilize our Barocycler instruments that are capitalized as fixed assets and depreciated over their expected useful life.
Inventories	Inventories are valued at the lower of cost (average cost) or market (sales price). The cost of Barocyclers consists of the cost charged by the contract manufacturer. The cost of manufactured goods includes material, freight-in, direct labor, and applicable overhead. The composition of inventory as of December 31 is as follows:
		2014				2013
	Raw materials	$	304,928			$	147,290
	Finished goods		595,624				639,386
	Inventory reserve		(50,000	)			(50,000	)
	Total	$	850,552			$	736,676
Property and Equipment	Property and equipment are stated at cost, less accumulated depreciation. For financial reporting purposes, depreciation is recognized using the straight-line method, allocating the cost of the assets over their estimated useful lives of three years for certain laboratory equipment, from three to five years for management information systems and office equipment, and three years for all PCT finished units classified as fixed assets.
Intangible Assets	We have classified as intangible assets, costs associated with the fair value of acquired intellectual property. Intangible assets, including patents, are being amortized on a straight-line basis over sixteen years. We perform an annual review of our intangible assets for impairment. When impairment is indicated, any excess of carrying value over fair value is recorded as a loss. An impairment analysis of intangible assets was performed as of December 31, 2014. Based on this analysis, we have concluded that no impairment of intangible assets had occurred.
Long-Lived Assets and Deferred Costs	The Company’s long-lived assets and other assets are reviewed for impairment in accordance with the guidance of the FASB ASC 360-10-05, Property, Plant, and Equipment, whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. Recoverability of an asset to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the asset. If such asset is considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds its fair value. Through December 31, 2014, the Company had not experienced impairment losses on its long-lived assets. While our current and historical operating losses and cash flow are indicators of impairment, we performed an impairment test at December 31, 2014 and determined that such long-lived assets were not impaired.
Concentrations	Credit Risk
	Our financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash, cash equivalents and trade receivables. We have cash investment policies which, among other things, limit investments to investment-grade securities. We perform ongoing credit evaluations of our customers, and the risk with respect to trade receivables is further mitigated by the fact that many of our customers are government institutions and university labs. Allowances are provided for estimated amounts of accounts receivable which may not be collected.  At December 31, 2014 and 2013, we determined that no allowance against accounts receivable was necessary.
	The following table illustrates the level of concentration of the below two groups within revenue as a percentage of total revenues during the years ended December 31:
		2014				2013
	Top Five Customers		32	%			53	%
	Federal Agencies		6	%			33	%
	The following table illustrates the level of concentration of the below two groups within accounts receivable as a percentage of total accounts receivable balance as of December 31:
		2014				2013
	Top Five Customers		86	%			86	%
	Federal Agencies		9	%			16	%
	Product Supply
	BIT Group USA, formerly Source Scientific, LLC, has been our sole contract manufacturer for all of our PCT instrumentation. Until we develop a broader network of manufacturers and subcontractors, obtaining alternative sources of supply or manufacturing services could involve significant delays and other costs and challenges, and may not be available to us on reasonable terms, if at all. The failure of a supplier or contract manufacturer to provide sufficient quantities, acceptable quality and timely products at an acceptable price, or an interruption of supplies from such a supplier could harm our business and prospects.
Computation of Loss per Share	Basic loss per share is computed by dividing loss available to common shareholders by the weighted average number of common shares outstanding. Diluted loss per share is computed by dividing loss available to common shareholders by the weighted average number of common shares outstanding plus additional common shares that would have been outstanding if dilutive potential common shares had been issued. For purposes of this calculation, convertible preferred stock, common stock dividends, warrants to acquire preferred stock convertible into common stock, and warrants and options to acquire common stock, are all considered common stock equivalents in periods in which they have a dilutive effect and are excluded from this calculation in periods in which these are anti-dilutive. The following table illustrates our computation of loss per share for the years ended December 31, 2014 and 2013.
		For the Year Ended
		December 31,
		2014				2013
	Numerator:
	Net loss	$	(4,612,540	)		$	(4,084,427	)
	Beneficial conversion feature for preferred stock		(1,495,415	)			(1,002,602	)
	Preferred dividends accrued		(143,771	)			(100,420	)
	Preferred dividends paid in cash		-				(60,000	)
	Net loss applicable to common shareholders	$	(6,251,726	)		$	(5,247,449	)
	Denominator for basic and diluted loss per share:
	Weighted average  common shares outstanding		14,264,753				11,821,870
	Loss per common share - basic and diluted	$	(0.44	)		$	(0.44	)
	The following table presents securities that could potentially dilute basic loss per share in the future. For all periods presented, the potentially dilutive securities were not included in the computation of diluted loss per share because these securities would have been anti-dilutive for the years ended December 31:
		2014				2013
	Stock options		3,406,250				1,771,708
	Convertible debt		5,453,571				2,242,024
	Common stock warrants		19,182,201				15,012,327
	Convertible preferred stock:
	Series D Convertible Preferred		750,000				750,000
	Series G Convertible Preferred		865,700				1,453,200
	Series H Convertible Preferred		1,000,000				1,000,000
	Series H2 Convertible Preferred		2,100,000				-
	Series J Convertible Preferred		3,546,000				5,087,500
	Series K Convertible Preferred		11,416,000				4,000,000
			47,719,722				31,316,759
Accounting for Income Taxes	We account for income taxes under the asset and liability method, which requires recognition of deferred tax assets, subject to valuation allowances, and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting and income tax purposes. The Company considers many factors when assessing the likelihood of future realization of our deferred tax assets, including recent cumulative earnings experience by taxing jurisdiction, expectations of future taxable income or loss, the carry-forward periods available to us for tax reporting purposes, and other relevant factors. A valuation allowance is established if it is more likely than not that all or a portion of the net deferred tax assets will not be realized. If substantial changes in the Company’s ownership should occur, as defined in Section 382 of the Internal Revenue Code, there could be significant limitations on the amount of net loss carry forwards that could be used to offset future taxable income.
Accounting for Stock-Based Compensation	We maintain equity compensation plans under which incentive stock options and non-qualified stock options are granted to employees, independent members of our Board of Directors and outside consultants. We recognize equity compensation expense over the requisite service period using the Black-Scholes formula to estimate the fair value of the stock options on the date of grant.
	Determining Fair Value of Stock Option Grants
	Valuation and Amortization Method - The fair value of each option award is estimated on the date of grant using the Black-Scholes pricing model based on certain assumptions. The estimated fair value of employee stock options is amortized to expense using the straight-line method over the vesting period, which generally is over three years.
	Expected Term - The Company uses the simplified calculation of expected life, described in the FASB ASC 718, Compensation-Stock Compensation, as the Company does not currently have sufficient historical exercise data on which to base an estimate of expected term. Using this method, the expected term is determined using the average of the vesting period and the contractual life of the stock options granted.
	Expected Volatility - Expected volatility is based on the Company’s historical stock volatility data over the expected term of the award.
	Risk-Free Interest Rate - The Company bases the risk-free interest rate used in the Black-Scholes valuation method on the implied yield currently available on U.S. Treasury zero-coupon issues with an equivalent remaining term.
	Forfeitures - As required by FASB ASC 718, Compensation-Stock Compensation, the Company records stock-based compensation expense only for those awards that are expected to vest. The Company estimated a forfeiture rate of 5% for awards granted based on historical experience and future expectations of options vesting. We used this historical rate as our assumption in calculating future stock-based compensation expense.
	The following table summarizes the assumptions we utilized for grants of stock options to the three sub-groups of our stock option recipients during the twelve months ended December 31, 2014 and 2013:
	Assumptions	Non-Employee Board Members			CEO, other Officers and Employees
	Expected life	6.0 (yrs)			6.0 (yrs)
	Expected volatility	134.75%-141.15%			132.2%-141.15%
	Risk-free interest rate	1.90%-2.54%			1.09%-2.54%
	Forfeiture rate	5.00%			5.00%
	Expected dividend yield	0.00%			0.00%
	We recognized stock-based compensation expense of $101,125 and $136,796 for the years ended December 31, 2014 and 2013, respectively. The following table summarizes the effect of this stock-based compensation expense within each of the line items within our accompanying Consolidated Statements of Operations for the years ended December 31:
		2014				2013
	Research and development	$	30,550			$	53,509
	Selling and marketing		19,792				26,551
	General and administrative		50,783				56,736
	Total stock-based compensation expense	$	101,125			$	136,796
	During the years ended December 31, 2014 and 2013, the total fair value of stock options awarded was $401,617 and $128,642, respectively.
	As of December 31, 2014, the total estimated fair value of unvested stock options to be amortized over their remaining vesting period was $323,811. The non-cash, stock based compensation expense associated with the vesting of these options will be $181,992 in 2015, $82,761 in 2016, and $59,058 in 2017.
Fair Value of Financial Instruments	Due to their short maturities, the carrying amounts for cash and cash equivalents, accounts receivable, accounts payable, and accrued expenses approximate their fair value. Short-term and long-term liabilities are primarily related to liabilities transferred under contractual arrangements with carrying values that approximate fair value.
Advertising	Advertising costs are expensed as incurred. We did not spend anything on advertising in 2014 or 2013.
Fair Value Measurements	The Company follows the guidance of FASB ASC Topic 820, “Fair Value Measurements and Disclosures” (“ASC 820”) as it related to financial assets and financial liabilities that are recognized or disclosed at fair value in the financial statements on a recurring basis.
	The Company generally defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). The Company uses a three-tier fair value hierarchy, which classifies the inputs used in measuring fair values. These tiers include: Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions.
	Financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company has determined that it does not have any financial assets measured at fair value and that its financial liabilities are currently all classified within Level 3 in the fair value hierarchy.
	The following tables set forth the Company’s financial liabilities that were accounted for at fair value on a recurring basis as of December 31, 2014 and December 31, 2013. The assumptions used to determine fair value of the warrants are contained in the table in Note 9 of the accompanying consolidated financial statements. The development of the unobservable inputs for Level 3 fair value measurements and fair value calculations are the responsibility of the Company’s management.
						Fair value measurements at December 31, 2014 using:
		31-Dec-14				Quoted prices in active markets (Level 1)			Significant other observable inputs (Level 2)			Significant unobservable inputs (Level 3)
	Series D common stock Purchase Warrants	$	159,875			$	-		$	-		$	159,875
						Fair value measurements at December 31, 2013 using:
		31-Dec-13				Quoted prices in active markets (Level 1)			Significant other observable inputs (Level 2)			Significant unobservable inputs (Level 3)
	Series D common stock Purchase Warrants	$	344,570			$	-		$	-		$	344,570
		January 1,				Change in Fair Value			Reclassification into equity			31-Dec-14
		2014
	Series D common stock Purchase Warrants	$	344,570			$	145,710		$	(330,405	)	$	159,875
		1-Jan-13				Change in Fair Value			31-Dec-13
	Series D common stock Purchase Warrants	$	160,812			$	183,758		$	344,570
						Fair value measurements at December 31, 2014 using:
		31-Dec-14				Quoted prices in active markets (Level 1)			Significant other observable inputs (Level 2)			Significant unobservable inputs (Level 3)
	July 7, 2014 note, conversion option	$	53,673				-			-		$	53,673
	July 7, 2014 note, conversion option		70,604				-			-			70,604
	August 28, 2014 note, conversion option		25,146				-			-			25,146
	September 3, 2014 note, conversion option		95,938				-			-			95,938
	September 10, 2014 note, conversion option		99,124				-			-			99,124
	September 26, 2014 note, conversion option		92,699				-			-			92,699
	November 10, 2014 note, conversion option		74,343										74,343
	November 17, 2014 note, conversion option		78,814				-			-			78,814
	Embedded conversion options	$	590,341				-			-		$	590,341
		Jan. 1, 2014				Issuance fair value			Change in fair value			Reclassification into equity			Dec. 31, 2014
	April 11, 2013 note, conversion option	$	130,734			$	-		$	7,348		$	(138,082	)	$	-
	June 26, 2013 note, conversion option		55,307				-			6,118			(61,425	)		-
	December 4, 2013 note, conversion option		98,129				-			(98,129	)		-			-
	December 23, 2013 note, conversion option		72,027				-			48,804			(120,831	)		-
	June 4, 2014 note, conversion option		-				57,071			(57,071	)		-			-
	July 7, 2014 note, conversion option		-				64,233			(10,560	)		-			53,673
	July 7, 2014 note, conversion option		-				89,926			(19,322	)		-			70,604
	August 28, 2014 note conversion option						36,892			(11,746	)					25,146
	September 3 2014 note, conversion option		-				122,340			(26,402	)		-			95,938
	September 10, 2014 note, conversion option		-				129,710			(30,586	)		-			99,124
	September 26, 2014 note, conversion option		-				140,060			(47,361	)		-			92,699
	November 10, 2014 note, conversion option						136,021			(61,678	)					74,343
	November 17, 2014 note, conversion option		-				122,431			(43,617	)		-			78,814
	Embedded conversion options	$	356,197			$	898,684		$	(344,202	)	$	(320,338	)	$	590,341
	The assumptions for the binomial pricing model are represented in the table below for the conversion options reflected on a per share common stock equivalent basis.
	Assumptions	11-Apr-13				Conversion options revalued at February 10, 2014
	Expected life (in months)		12				2
	Expected volatility		206.2	%			119.7	%
	Risk-free interest rate		0.1	%			0.04	%
	Exercise price	$	0.14			$	0.25
	Fair value per conversion option	$	0.29			$	0.2
	Assumptions	26-Jun-13				Conversion options revalued at February 10, 2014
	Expected life (in months)		12				5
	Expected volatility		189.2	%			137.9	%
	Risk-free interest rate		0.13	%			0.07	%
	Exercise price	$	0.17			$	0.25
	Fair value per conversion option	$	0.25			$	0.23
	Assumptions	4-Dec-13				Conversion options revalued at June 30, 2014
	Expected life (in months)		24				1
	Expected volatility		170.3	%			77.1	%
	Risk-free interest rate		0.3	%			0.02	%
	Exercise price	$	0.4			$	0.4
	Fair value per conversion option	$	0.16			$	0.02
	Assumptions	23-Dec-13				Conversion options revalued at June 23, 2014
	Expected life (in months)		36				30
	Expected volatility		151.4	%			159.2	%
	Risk-free interest rate		0.77	%			0.73	%
Exercise price	$	0.4			$	0.4
Fair value per conversion option	$	0.17			$	0.32
Assumptions	4-Jun-14				Conversion options revalued at Dec. 31, 2014
Expected life (in months)		8				1
Expected volatility		121.8	%			77.4	%
Risk-free interest rate		0.07	%			0.03	%
Exercise price	$	0.45			$	0.45
Fair value per conversion option	$	0.16			$	0
Assumptions	7-Jul-14				Conversion options revalued at Dec. 31, 2014
Expected life (in months)		12				6
Expected volatility		117.9	%			114.7	%
Risk-free interest rate		0.12	%			0.12	%
Exercise price	$	0.21			$	0.16
Fair value per conversion option	$	0.18			$	0.11
Assumptions	7-Jul-14				Conversion options revalued at Dec. 31, 2014
Expected life (in months)		12				6
Expected volatility		117.9	%			114.7	%
Risk-free interest rate		0.12	%			0.12	%
Exercise price	$	0.21			$	0.17
Fair value per conversion option	$	0.18			$	0.11
Assumptions	28-Aug-14				Conversion options revalued at Dec. 31, 2014
Expected life (in months)		6				2
Expected volatility		104.4	%			121.7	%
Risk-free interest rate		0.05	%			0.04	%
Exercise price	$	0.14			$	0.15
Fair value per conversion option	$	0.15			$	0.11
Assumptions	Sept. 3, 2014				Conversion options revalued at Dec.31, 2014
Expected life (in months)		36				32
Expected volatility		153.8	%			154.1	%
Risk-free interest rate		0.99	%			0.88	%
Exercise price	$	0.35			$	0.35
Fair value per conversion option	$	0.24			$	0.19
Assumptions	Sept. 10, 2014				Conversion options revalued at Dec. 31, 2014
Expected life (in months)		12				8
Expected volatility		117.6	%			106.6	%
Risk-free interest rate		0.12	%			0.18	%
Exercise price	$	0.13			$	0.14
Fair value per conversion option	$	0.17			$	0.14
Assumptions	Sept. 26, 2014				Conversion options revalued at Dec. 31, 2014
Expected life (in months)		12				9
Expected volatility		116.6	%			106.2	%
Risk-free interest rate		0.11	%			0.17	%
Exercise price	$	0.16			$	0.15
Fair value per conversion option	$	0.19			$	0.13
Assumptions	Nov. 10, 2014				Conversion options revalued at Dec. 31, 2014
Expected life (in months)		10				8
Expected volatility		104.2	%			106.6	%
Risk-free interest rate		0.1	%			0.18	%
Exercise price	$	0.13			$	0.14
Fair value per conversion option	$	0.23			$	0.14
Assumptions	Nov. 17, 2014				Conversion options revalued at Dec. 31, 2014
Expected life (in months)		12				10
Expected volatility		117.9	%			107.1	%
Risk-free interest rate		0.12	%			0.15	%
Exercise price	$	0.17			$	0.17
Fair value per conversion option	$	0.2			$	0.13

2_Summary_of_Significant_Accou2

2. Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2014
Notes to Financial Statements
Inventories Table		2014				2013
	Raw materials	$	304,928			$	147,290
	Finished goods		595,624				639,386
	Inventory reserve		(50,000	)			(50,000	)
	Total	$	850,552			$	736,676
Customer Concentration	The following table illustrates the level of concentration of the below two groups within revenue as a percentage of total revenues during the years ended December 31:
		2014				2013
	Top Five Customers		32	%			53	%
	Federal Agencies		6	%			33	%
	The following table illustrates the level of concentration of the below two groups within accounts receivable as a percentage of total accounts receivable balance as of December 31:
		2014				2013
	Top Five Customers		86	%			86	%
	Federal Agencies		9	%			16	%
Computation of Loss per Share		For the Year Ended
		December 31,
		2014				2013
	Numerator:
	Net loss	$	(4,612,540	)		$	(4,084,427	)
	Beneficial conversion feature for preferred stock		(1,495,415	)			(1,002,602	)
	Preferred dividends accrued		(143,771	)			(100,420	)
	Preferred dividends paid in cash		-				(60,000	)
	Net loss applicable to common shareholders	$	(6,251,726	)		$	(5,247,449	)
	Denominator for basic and diluted loss per share:
	Weighted average  common shares outstanding		14,264,753				11,821,870
	Loss per common share - basic and diluted	$	(0.44	)		$	(0.44	)
Schedule of antidilutive securities
		2014				2013
	Stock options		3,406,250				1,771,708
	Convertible debt		5,453,571				2,242,024
	Common stock warrants		19,182,201				15,012,327
	Convertible preferred stock:
	Series D Convertible Preferred		750,000				750,000
	Series G Convertible Preferred		865,700				1,453,200
	Series H Convertible Preferred		1,000,000				1,000,000
	Series H2 Convertible Preferred		2,100,000				-
	Series J Convertible Preferred		3,546,000				5,087,500
	Series K Convertible Preferred		11,416,000				4,000,000
			47,719,722				31,316,759
Fair value assumptions	Assumptions	Non-Employee Board Members			CEO, other Officers and Employees
	Expected life	6.0 (yrs)			6.0 (yrs)
	Expected volatility	134.75%-141.15%			132.2%-141.15%
	Risk-free interest rate	1.90%-2.54%			1.09%-2.54%
	Forfeiture rate	5.00%			5.00%
	Expected dividend yield	0.00%			0.00%
	The assumptions for the binomial pricing model are represented in the table below for the conversion options reflected on a per share common stock equivalent basis.
	Assumptions	11-Apr-13				Conversion options revalued at February 10, 2014
	Expected life (in months)		12				2
	Expected volatility		206.2	%			119.7	%
	Risk-free interest rate		0.1	%			0.04	%
	Exercise price	$	0.14			$	0.25
	Fair value per conversion option	$	0.29			$	0.2
	Assumptions	26-Jun-13				Conversion options revalued at February 10, 2014
	Expected life (in months)		12				5
	Expected volatility		189.2	%			137.9	%
	Risk-free interest rate		0.13	%			0.07	%
	Exercise price	$	0.17			$	0.25
	Fair value per conversion option	$	0.25			$	0.23
	Assumptions	4-Dec-13				Conversion options revalued at June 30, 2014
	Expected life (in months)		24				1
	Expected volatility		170.3	%			77.1	%
	Risk-free interest rate		0.3	%			0.02	%
	Exercise price	$	0.4			$	0.4
	Fair value per conversion option	$	0.16			$	0.02
	Assumptions	23-Dec-13				Conversion options revalued at June 23, 2014
	Expected life (in months)		36				30
	Expected volatility		151.4	%			159.2	%
	Risk-free interest rate		0.77	%			0.73	%
	Exercise price	$	0.4			$	0.4
	Fair value per conversion option	$	0.17			$	0.32
	Assumptions	4-Jun-14				Conversion options revalued at Dec. 31, 2014
	Expected life (in months)		8				1
	Expected volatility		121.8	%			77.4	%
	Risk-free interest rate		0.07	%			0.03	%
	Exercise price	$	0.45			$	0.45
	Fair value per conversion option	$	0.16			$	-
	Assumptions	7-Jul-14				Conversion options revalued at Dec. 31, 2014
	Expected life (in months)		12				6
	Expected volatility		117.9	%			114.7	%
	Risk-free interest rate		0.12	%			0.12	%
	Exercise price	$	0.21			$	0.16
	Fair value per conversion option	$	0.18			$	0.11
	Assumptions	7-Jul-14				Conversion options revalued at Dec. 31, 2014
	Expected life (in months)		12				6
	Expected volatility		117.9	%			114.7	%
	Risk-free interest rate		0.12	%			0.12	%
	Exercise price	$	0.21			$	0.17
	Fair value per conversion option	$	0.18			$	0.11
	Assumptions	28-Aug-14				Conversion options revalued at Dec. 31, 2014
	Expected life (in months)		6				2
	Expected volatility		104.4	%			121.7	%
	Risk-free interest rate		0.05	%			0.04	%
	Exercise price	$	0.14			$	0.15
	Fair value per conversion option	$	0.15			$	0.11
	Assumptions	Sept. 3, 2014				Conversion options revalued at Dec.31, 2014
	Expected life (in months)		36				32
	Expected volatility		153.8	%			154.1	%
	Risk-free interest rate		0.99	%			0.88	%
	Exercise price	$	0.35			$	0.35
	Fair value per conversion option	$	0.24			$	0.19
	Assumptions	Sept. 10, 2014				Conversion options revalued at Dec. 31, 2014
	Expected life (in months)		12				8
	Expected volatility		117.6	%			106.6	%
Risk-free interest rate		0.12	%			0.18	%
Exercise price	$	0.13			$	0.14
Fair value per conversion option	$	0.17			$	0.14
Assumptions	Sept. 26, 2014				Conversion options revalued at Dec. 31, 2014
Expected life (in months)		12				9
Expected volatility		116.6	%			106.2	%
Risk-free interest rate		0.11	%			0.17	%
Exercise price	$	0.16			$	0.15
Fair value per conversion option	$	0.19			$	0.13
Assumptions	Nov. 10, 2014				Conversion options revalued at Dec. 31, 2014
Expected life (in months)		10				8
Expected volatility		104.2	%			106.6	%
Risk-free interest rate		0.1	%			0.18	%
Exercise price	$	0.13			$	0.14
Fair value per conversion option	$	0.23			$	0.14
Assumptions	Nov. 17, 2014				Conversion options revalued at Dec. 31, 2014
Expected life (in months)		12				10
Expected volatility		117.9	%			107.1	%
Risk-free interest rate		0.12	%			0.15	%
Exercise price	$	0.17			$	0.17
Fair value per conversion option	$	0.2			$	0.13
Stock based compensation expense		2014				2013
	Research and development	$	30,550			$	53,509
	Selling and marketing		19,792				26,551
	General and administrative		50,783				56,736
	Total stock-based compensation expense	$	101,125			$	136,796
Liabilities measured at fair value on recurring basis
						Fair value measurements at December 31, 2014 using:
		31-Dec-14				Quoted prices in active markets (Level 1)			Significant other observable inputs (Level 2)			Significant unobservable inputs (Level 3)
	Series D common stock Purchase Warrants	$	159,875			$	-		$	-		$	159,875
						Fair value measurements at December 31, 2013 using:
		31-Dec-13				Quoted prices in active markets (Level 1)			Significant other observable inputs (Level 2)			Significant unobservable inputs (Level 3)
	Series D common stock Purchase Warrants	$	344,570			$	-		$	-		$	344,570
		January 1,				Change in Fair Value			Reclassification into equity			31-Dec-14
		2014
	Series D common stock Purchase Warrants	$	344,570			$	145,710		$	(330,405	)	$	159,875
		1-Jan-13				Change in Fair Value			31-Dec-13
	Series D common stock Purchase Warrants	$	160,812			$	183,758		$	344,570
						Fair value measurements at December 31, 2014 using:
		31-Dec-14				Quoted prices in active markets (Level 1)			Significant other observable inputs (Level 2)			Significant unobservable inputs (Level 3)
	July 7, 2014 note, conversion option	$	53,673				-			-		$	53,673
	July 7, 2014 note, conversion option		70,604				-			-			70,604
	August 28, 2014 note, conversion option		25,146				-			-			25,146
	September 3, 2014 note, conversion option		95,938				-			-			95,938
	September 10, 2014 note, conversion option		99,124				-			-			99,124
	September 26, 2014 note, conversion option		92,699				-			-			92,699
	November 10, 2014 note, conversion option		74,343										74,343
	November 17, 2014 note, conversion option		78,814				-			-			78,814
	Embedded conversion options	$	590,341				-			-		$	590,341
		Jan. 1, 2014				Issuance fair value			Change in fair value			Reclassification into equity			Dec. 31, 2014
	April 11, 2013 note, conversion option	$	130,734			$	-		$	7,348		$	(138,082	)	$	-
	June 26, 2013 note, conversion option		55,307				-			6,118			(61,425	)		-
	December 4, 2013 note, conversion option		98,129				-			(98,129	)		-			-
	December 23, 2013 note, conversion option		72,027				-			48,804			(120,831	)		-
	June 4, 2014 note, conversion option		-				57,071			(57,071	)		-			-
	July 7, 2014 note, conversion option		-				64,233			(10,560	)		-			53,673
	July 7, 2014 note, conversion option		-				89,926			(19,322	)		-			70,604
	August 28, 2014 note conversion option						36,892			(11,746	)					25,146
	September 3 2014 note, conversion option		-				122,340			(26,402	)		-			95,938
	September 10, 2014 note, conversion option		-				129,710			(30,586	)		-			99,124
	September 26, 2014 note, conversion option		-				140,060			(47,361	)		-			92,699
	November 10, 2014 note, conversion option						136,021			(61,678	)					74,343
	November 17, 2014 note, conversion option		-				122,431			(43,617	)		-			78,814
	Embedded conversion options	$	356,197			$	898,684		$	(344,202	)	$	(320,338	)	$	590,341

3_Property_and_Equipment_net_T

3. Property and Equipment, net (Tables)	12 Months Ended
	Dec. 31, 2014
Property, Plant and Equipment [Abstract]
Property and equipment		December 31,
		2014			2013
	Laboratory and manufacturing equipment	$	226,081		$	226,081
	Office equipment		149,459			142,323
	Leasehold improvements		8,117			8,117
	PCT collaboration, demonstration and leased systems		461,858			461,858
	Total property and equipment		845,515			838,379
	Less accumulated depreciation		(809,490	)		(780,277	)
	Net book value	$	36,025		$	58,102

4_Intangible_Assets_net_Tables

4. Intangible Assets, net (Tables)	12 Months Ended
	Dec. 31, 2014
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets		December 31,
		2014			2013
	PCT Patents	$	778,156		$	778,156
	Less accumulated amortization		(778,156	)		(741,658	)
	Net book value	$	-		$	36,498

6_Income_Taxes_Tables

6. Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Deferred tax assets and deferred tax liabilities		December 31,
	Current deferred taxes	2014			2013
	Inventories	$	19,640		$	19,640
	Other accruals		21,818			23,050
	Less: valuation allowance		(41,458	)		(42,690	)
	Total current deferred tax assets	$	-		$	-
	Long term deferred taxes:
	Accelerated tax depreciation	$	12,162		$	29,511
	Non-cash, stock-based compensation, nonqualified		440,614			387,708
	Goodwill and intangibles		-			(14,337	)
	Operating loss carry forwards and tax credits		9,720,260			8,938,681
	Less: valuation allowance		(10,173,036	)		(9,341,563	)
	Total long term deferred tax assets (liabilities), net		-			-
	Total net deferred tax liabilities	$	-		$	-
Effective income tax (benefit) provision rate		2014			2013
	Federal tax provision rate		34	%		34	%
	Permanent differences		(2	) %		(3	) %
	State tax expense		0	%		0	%
	Refundable AMT and R&D tax credit		0	%		0	%
	Net operating loss carry back		0	%		0	%
	Valuation allowance		(32	) %		(31	) %
	Effective income tax provision		0	%		0	%

7_Commitments_and_Contingencie1

7. Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
Future minimum rental payments required under operating leases	2015	$	94,272
	Thereafter		73,344
	Total minimum payments required	$	167,616

9_Stockholders_Deficit_Tables

9. Stockholders' (Deficit) (Tables)	12 Months Ended
	Dec. 31, 2014
Stockholders Deficit Tables
Assumptions used	Assumptions	Series J warrants February 6, 2013			Series J warrants March 28, 2013			Series J warrants May 20, 2013
	Contractual life (in months)		36			36			36
	Expected volatility		141.8			144.3			147
	Risk-free interest rate		0.39	%		0.36	%		0.36	%
	Exercise price	$	0.4		$	0.4		$	0.4
	Fair value per warrant	$	0.36		$	0.26		$	0.3
Options and warrants outstanding and exercisable	The following tables summarize information concerning options and warrants outstanding and exercisable:
		Stock Options						Warrants
		Weighted						Weighted
		Average price						Average price						Total
		Shares			per share			Shares			per share			Shares			Exercisable
	Balance outstanding, January 1, 2013		1,605,750		$	0.8			6,687,099		$	0.81			8,292,849			7,989,331
	Granted		363,500			0.41			8,346,228			0.37			8,709,728
	Exercised		-			-			-			-			-
	Expired		(10,000	)		1			(21,000	)		2.38			(31,000	)
	Forfeited		(187,542	)		0.85			-			-			(187,542	)
	Balance outstanding, December 31, 2013		1,771,708		$	0.71			15,012,327		$	0.57			16,784,035			16,611,528
	Granted		1,675,500			0.3			8,903,000			0.38			10,578,500
	Exercised		-			-			(4,208,658	)		0.25			(4,208,658	)
	Expired		(10,000	)		1			(524,468	)		0.74			(534,468	)
	Forfeited		(30,985	)		0.71			-			-			(30,958	)
	Balance outstanding, December 31, 2014		3,406,250		$	0.51			19,182,201		$	0.49			22,588,451			20,858,111
	The weighted average grant date fair value of options issued was $0.25 for the year ending December 31, 2014.
			Options Outstanding									Options Exercisable
						Weighted Average									Weighted Average
	Range of Exercise Prices		Number of Options			Remaining Contractual Life (Years)			Exercise Price			Number of Options			Remaining Contractual Life (Years)			Exercise Price
	$0.30-$0.39			1,675,500			9.7		$	0.3			-			-		$	-
	0.40-0.49			311,000			8.4			0.4			311,000			8.4			0.4
	0.50-0.59			251,250			7.6			0.5			251,250			7.6			0.5
	0.60-0.69			467,500			5			0.6			433,283			4.8			0.6
	0.70-1.25			701,000			2.2			1			680,377			2.1			1
	$0.30-$1.25			3,406,250			5.1		$	0.51			1,675,910			4.8		$	0.72

2_Summary_of_Significant_Accou3

2. Summary of Significant Accounting Policies (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Summary Of Significant Accounting Policies Details
Raw materials	$304,928	$147,290
Finished Goods	595,624	639,386
Inventory Reserve	-50,000	-50,000
Total	$850,552	$736,676

2_Summary_of_Significant_Accou4

2. Summary of Significant Accounting Policies (Details 1)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Summary Of Significant Accounting Policies Details 1
Top Five Customers by percentage of total revenue	32.00%	53.00%
Federal Agencies percentage of total revenue	6.00%	33.00%
Top Five Customers percentage of total receivables	86.00%	86.00%
Federal Agencies percentage of total receivables	9.00%	16.00%

2_Summary_of_Significant_Accou5

2. Summary of Significant Accounting Policies (Details 2) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Numerator:
Net loss	($4,612,540)	($4,084,427)
Beneficial conversion feature for preferred stock	-1,495,415	-1,002,602
Preferred dividends accrued	-143,771	-100,420
Preferred dividends paid in cash	0	-60,000
Net loss applicable to common shareholders	($6,251,726)	($5,247,449)
Denominator for basic and diluted loss per share:
Weighted average common stock shares outstanding	14,264,753	11,821,870
Loss per common share - basic and diluted	($0.44)	($0.44)

2_Summary_of_Significant_Accou6

2. Summary of Significant Accounting Policies (Details 3)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Summary Of Significant Accounting Policies Details 3
Stock options	3,406,250	1,771,708
Convertible debt	5,453,571	2,242,024
Common stock warrants	19,182,201	15,012,327
Convertible preferred stock:
Series D Convertible Preferred stock	750,000	750,000
Series G Convertible Preferred stock	865,700	1,453,200
Series H Convertible Preferred stock	1,000,000	1,000,000
Series H2 Convertible Preferred	2,100,000	0
Series J Convertible Preferred stock	3,546,000	5,087,500
Series K Convertible Preferred stock	11,416,000	4,000,000
Total potentially dilutive shares	47,719,722	31,316,759

2_Summary_of_Significant_Accou7

2. Summary of Significant Accounting Policies (Details 4)	12 Months Ended
	Dec. 31, 2014
Non-Employee Board Members
Expected life	6 years
Expected volatility Minimum	134.75%
Expected volatility Maximum	141.15%
Risk-free interest rate Minimum	1.90%
Risk-free interest rate Maximum	2.54%
Forfeiture rate	5.00%
Expected dividend yield	0.00%
CEO, other Officers and Employees
Expected life	6 years
Expected volatility Minimum	132.20%
Expected volatility Maximum	141.15%
Risk-free interest rate Minimum	1.09%
Risk-free interest rate Maximum	2.54%
Forfeiture rate	5.00%
Expected dividend yield	0.00%

2_Summary_of_Significant_Accou8

2. Summary of Significant Accounting Policies (Details 5) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Total stock-based compensation expense	$101,125	$136,796
Research and Development
Total stock-based compensation expense	30,550	53,509
Selling and Marketing
Total stock-based compensation expense	19,792	26,551
General and Administrative
Total stock-based compensation expense	$50,783	$56,736

2_Summary_of_Significant_Accou9

2. Summary of Significant Accounting Policies (Details 6) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Change in fair value	$145,710	$183,758
Reclassification to equity	-330,405
Quoted Prices in active markets (Level 1)
Series D common stock Purchase Warrants	0	0
Significant Other Observable Inputs Level 2
Series D common stock Purchase Warrants	0	0
Significant Unobservable Inputs Level 3
Series D common stock Purchase Warrants	159,875	344,570
Total Fair Value
Series D common stock Purchase Warrants	$159,875	$344,570

Recovered_Sheet1

2. Summary of Significant Accounting Policies (Details 7) (USD $)	Dec. 31, 2014	Dec. 31, 2013
April 11, 2013 note, conversion option		$130,734
June 26, 2013 note, conversion option		55,307
December 4, 2013 note, conversion option		98,129
December 23, 2013 note, conversion option		72,027
June 4, 2014 note, conversion option
July 7, 2014 note, conversion option	53,673
July 7, 2014 note, conversion option	70,604
August 28, 2014 note conversion option	25,146
September 3 2014 note, conversion option	95,938
September 10, 2014 note, conversion option	99,124
September 26, 2014 note, conversion option	92,699
November 10, 2014 note, conversion option	74,343
November 17, 2014 note, conversion option	78,814
Embedded conversion options	590,341	356,197
Issuance fair value [Member]
April 11, 2013 note, conversion option
June 26, 2013 note, conversion option
December 4, 2013 note, conversion option
December 23, 2013 note, conversion option
June 4, 2014 note, conversion option	57,071
July 7, 2014 note, conversion option	64,233
July 7, 2014 note, conversion option	89,926
August 28, 2014 note conversion option	36,892
September 3 2014 note, conversion option	122,340
September 10, 2014 note, conversion option	129,710
September 26, 2014 note, conversion option	140,060
November 10, 2014 note, conversion option	136,021
November 17, 2014 note, conversion option	122,431
Embedded conversion options	898,684
Change in Fair Value [Member]
April 11, 2013 note, conversion option	7,348
June 26, 2013 note, conversion option	6,118
December 4, 2013 note, conversion option	-98,129
December 23, 2013 note, conversion option	48,804
June 4, 2014 note, conversion option	-57,071
July 7, 2014 note, conversion option	-10,560
July 7, 2014 note, conversion option	-19,322
August 28, 2014 note conversion option	-11,746
September 3 2014 note, conversion option	-26,402
September 10, 2014 note, conversion option	-30,586
September 26, 2014 note, conversion option	-47,361
November 10, 2014 note, conversion option	-61,678
November 17, 2014 note, conversion option	-43,617
Embedded conversion options	-344,202
Reclassification into equity
April 11, 2013 note, conversion option	-138,082
June 26, 2013 note, conversion option	-61,425
December 4, 2013 note, conversion option
December 23, 2013 note, conversion option	-120,831
June 4, 2014 note, conversion option
July 7, 2014 note, conversion option
July 7, 2014 note, conversion option
September 3 2014 note, conversion option
September 10, 2014 note, conversion option
September 26, 2014 note, conversion option
November 17, 2014 note, conversion option
Embedded conversion options	-320,338
Quoted Prices in active markets (Level 1)
July 7, 2014 note, conversion option
July 7, 2014 note, conversion option
August 28, 2014 note conversion option
September 3 2014 note, conversion option
September 10, 2014 note, conversion option
September 26, 2014 note, conversion option
November 17, 2014 note, conversion option
Embedded conversion options
Significant Other Observable Inputs Level 2
July 7, 2014 note, conversion option
July 7, 2014 note, conversion option
August 28, 2014 note conversion option
September 3 2014 note, conversion option
September 10, 2014 note, conversion option
September 26, 2014 note, conversion option
November 17, 2014 note, conversion option
Embedded conversion options
Significant Unobservable Inputs Level 3
July 7, 2014 note, conversion option	53,673
July 7, 2014 note, conversion option	70,604
August 28, 2014 note conversion option	25,146
September 3 2014 note, conversion option	95,938
September 10, 2014 note, conversion option	99,124
September 26, 2014 note, conversion option	92,699
November 10, 2014 note, conversion option	74,343
November 17, 2014 note, conversion option	78,814
Embedded conversion options	$590,341

3_Summary_of_Significant_Accou

3. Summary of Significant Accounting Policies (Details 8) (USD $)	0 Months Ended	1 Months Ended
	Sep. 03, 2014	Sep. 26, 2014	Sep. 10, 2014	Aug. 28, 2014	Jun. 04, 2014	Dec. 23, 2013	Dec. 04, 2013	Jun. 26, 2013	Apr. 11, 2013	Dec. 31, 2014	Jul. 07, 2014	Feb. 10, 2014	Jun. 30, 2014	Jun. 23, 2014	Sep. 30, 2014
Expected life (in months)	36 months	12 months	12 months	6 months	8 months	36 months	24 months	12 months	12 months
Expected volatility	153.80%	116.60%	117.60%	104.40%	121.80%	151.40%	170.30%	189.20%	206.20%
Risk-free interest rate	0.99%	0.11%	0.12%	0.05%	0.07%	0.77%	0.30%	0.13%	0.10%
Exercise price	$0.35	$0.16	$0.13	$0.14	$0.45	$0.40	$0.40	$0.17	$0.14
Fair value per warrant	$0.24	$0.19	$0.12	$0.15	$0.16	$0.17	$0.16	$0.25	$0.29
Transaction 1 [Member]
Expected life (in months)										6 months	12 months
Expected volatility										111.47%	117.90%
Risk-free interest rate										0.12%	0.12%
Exercise price										$0.16	$0.21
Fair value per warrant										$0.11	$0.18
Transaction 2 [Member]
Expected life (in months)										6 months	12 months
Expected volatility										111.47%	117.90%
Risk-free interest rate										0.12%	0.12%
Exercise price										$0.17	$0.21
Fair value per warrant										$0.11	$0.18
Conversion options revalued Three [Member]
Expected life (in months)												2 months
Expected volatility												116.40%
Risk-free interest rate												0.04%
Exercise price												$0.25
Fair value per warrant												$0.20
Conversion options revalued Four [Member]
Expected life (in months)												5 months
Expected volatility												137.90%
Risk-free interest rate												0.07%
Exercise price												$0.25
Fair value per warrant												$0.23
Conversion options revalued one [Member]
Expected life (in months)													1 month
Expected volatility															77.10%
Risk-free interest rate															0.02%
Exercise price															$0.40
Fair value per warrant															$0.02
Conversion options revalued Two [Member]
Expected life (in months)														30 months
Expected volatility														159.20%
Risk-free interest rate														0.73%
Exercise price														$0.40
Fair value per warrant														$0.32
Conversion options revalued Six [Member]
Expected life (in months)										1 month
Expected volatility										77.40%
Risk-free interest rate										0.03%
Exercise price										$0.45
Fair value per warrant
Conversion options revalued Eight [Member]
Expected life (in months)										2 months
Expected volatility										121.70%
Risk-free interest rate										0.04%
Exercise price										$0.15
Fair value per warrant										$0.11
Conversion options revalued Nine [Member]
Expected life (in months)										32 months
Expected volatility										154.10%
Risk-free interest rate										0.88%
Exercise price										$0.35
Fair value per warrant										$0.19
Conversion options revalued Ten [Member]
Expected life (in months)										8 months
Expected volatility										106.60%
Risk-free interest rate										0.18%
Exercise price										$0.14
Fair value per warrant										$0.14
Conversion options revalued Eleven [Member]
Expected life (in months)										9 months
Expected volatility										106.20%
Risk-free interest rate										0.17%
Exercise price										$0.15
Fair value per warrant										$0.13

3_Property_and_Equipment_net_D

3. Property and Equipment, net (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Property And Equipment Net Details
Laboratory and manufacturing equipment	$226,081	$226,081
Office equipment	149,459	142,323
Leasehold improvements	8,117	8,117
PCT collaboration, demonstration and leased systems	461,858	461,858
Total property and equipment	845,515	838,379
Less accumulated depreciation	-809,490	-780,277
Net book value	$36,025	$58,102

4_Intangible_Assets_net_Detail

4. Intangible Assets, net (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Intangible Assets Net Details
PCT Patents	$778,156	$778,156
Less accumulated amortization	-778,156	-741,658
Net book value	$0	$36,498

5_Retirement_Plan_Details_Narr

5. Retirement Plan (Details Narrative) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Retirement Plan Details Narrative
Company-matching contributions	$10,022	$10,377

6_Income_Taxes_Details

6. Income Taxes (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Current deferred taxes
Inventories	$19,640	$19,640
Other accruals	21,818	23,050
Less: valuation allowance	-41,458	-42,690
Total current deferred tax assets	0	0
Long term deferred taxes:
Accelerated tax depreciation	12,162	29,511
Non-cash, stock-based compensation, nonqualified	440,614	387,708
Goodwill and intangibles	0	-14,337
Operating loss carry forwards and tax credits	9,720,260	8,938,681
Less: valuation allowance	-10,173,036	-9,341,563
Total long term deferred tax assets (liabilities), net	0	0
Total net deferred tax liabilities	$0	$0

6_Income_Taxes_Details_1

6. Income Taxes (Details 1)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Income Taxes Details 1
Federal tax provision rate	34.00%	34.00%
Permanent differences	-2.00%	-2.00%
State tax expense	0.00%	0.00%
Refundable AMT and R&D tax credit	0.00%	0.00%
Net operating loss carry back	0.00%	0.00%
Valuation allowance	-32.00%	-31.00%
Effective income tax provision	0.00%	0.00%

7_Commitments_and_Contingencie2

7. Commitments and Contingencies (Details) (USD $)	Dec. 31, 2013
Commitments And Contingencies Details
2015	$94,272
Thereafter	73,344
Total minimum payments required	$167,616

9_Stockholders_Deficit_Details

9. Stockholdersb (Deficit) (Details) (USD $)	12 Months Ended
	Dec. 31, 2014
Warrrants Series J Feb 2013
Contractual life, in years	36 months
Expected volatility	141.80%
Risk-free interest rate	0.39%
Exercise price	$0.40
Fair value per warrant	$0.36
Warrrants Series J March 2013
Contractual life, in years	36 months
Expected volatility	144.30%
Risk-free interest rate	0.36%
Exercise price	$0.40
Fair value per warrant	$0.26
Warrrants Series J May 2013
Contractual life, in years	36 months
Expected volatility	147.00%
Risk-free interest rate	0.36%
Exercise price	$0.40
Fair value per warrant	$0.30

9_Stockholders_Deficit_Details1

9. Stockholders' Deficit (Details 1) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Stock Options
Balance outstanding, Begining Balance	1,771,708	1,605,750
Granted	1,675,500	363,500
Exercised		0
Expired	-10,000	-10,000
Forfeited	-30,985	-187,542
Balance outstanding, Ending Balance	3,406,250	1,771,708
Weighted Average price per share, Beginning Balance	$0.71	$0.80
Weighted Average price per share, Granted	$0.30	$0.41
Weighted Average price per share, Exercised
Weighted Average price per share, Expired	$1	$1
Weighted Average price per share, Forfeited	$0.71	$0.85
Weighted Average price per share, Ending Balance	$0.51	$0.71
WarrantMember
Balance outstanding, Begining Balance	15,012,327	6,687,099
Granted	8,903,000	8,346,228
Exercised	-4,208,658
Expired	-524,468	-21,000
Forfeited
Balance outstanding, Ending Balance	19,182,201	15,012,327
Weighted Average price per share, Beginning Balance	$0.57	$0.81
Weighted Average price per share, Granted	$0.38	$0.37
Weighted Average price per share, Exercised	$0.25
Weighted Average price per share, Expired	$0.74	$2.38
Weighted Average price per share, Forfeited
Weighted Average price per share, Ending Balance	$0.49	$0.57
Exercisable [Member]
Balance outstanding, Begining Balance	16,784,035	8,292,849
Balance outstanding, Begining Balance, Exercisable	16,611,528	7,989,331
Granted	10,578,500	8,709,728
Exercised	-4,208,658
Expired	-534,468	-31,000
Forfeited	-30,958	-187,542
Balance outstanding, Ending Balance	22,588,451	16,784,035
Balance outstanding,Ending Balance for Exercisable	20,858,111	16,611,528

9_Stockholders_Deficit_Details2

9. Stockholder's Deficit (Details 2) (USD $)	12 Months Ended
	Dec. 31, 2014
Option 1
Lower Limit of Range of Exercise Prices	$0.30
Upper Limit Range of Exercise Prices	$0.39
Number Outstanding	1,675,500
Weighted Average Exercise Price, options outstanding	$0.30
Weighted Average Remaining Contractual Life	9 years 8 months 12 days
Number Exercisable	0
Weighted Average Exercise Price, options exercisable
Option 2
Lower Limit of Range of Exercise Prices	$0.40
Upper Limit Range of Exercise Prices	$0.49
Number Outstanding	311,000
Weighted Average Exercise Price, options outstanding	$0.40
Weighted Average Remaining Contractual Life	8 years 4 months 24 days
Number Exercisable	311,000
Weighted Average Exercise Price, options exercisable	$0.40
Weighted Average Remaining Contractual Life Options Exercisable	8 years 4 months 24 days
Option 3
Lower Limit of Range of Exercise Prices	$0.50
Upper Limit Range of Exercise Prices	$0.59
Number Outstanding	251,250
Weighted Average Exercise Price, options outstanding	$0.50
Weighted Average Remaining Contractual Life	7 years 7 months 6 days
Number Exercisable	251,250
Weighted Average Exercise Price, options exercisable	$0.50
Weighted Average Remaining Contractual Life Options Exercisable	7 years 7 months 6 days
Option 4
Lower Limit of Range of Exercise Prices	$0.60
Upper Limit Range of Exercise Prices	$0.69
Number Outstanding	467,500
Weighted Average Exercise Price, options outstanding	$0.60
Weighted Average Remaining Contractual Life	5 years
Number Exercisable	433,283
Weighted Average Exercise Price, options exercisable	$0.60
Weighted Average Remaining Contractual Life Options Exercisable	4 years 9 months 18 days
Option 5
Lower Limit of Range of Exercise Prices	$0.70
Upper Limit Range of Exercise Prices	$1.25
Number Outstanding	701,000
Weighted Average Exercise Price, options outstanding	$1
Weighted Average Remaining Contractual Life	2 years 2 months 12 days
Number Exercisable	680,377
Weighted Average Exercise Price, options exercisable	$1
Weighted Average Remaining Contractual Life Options Exercisable	2 years 1 month 6 days
Total Options
Lower Limit of Range of Exercise Prices	$0.30
Upper Limit Range of Exercise Prices	$1.25
Number Outstanding	3,406,250
Weighted Average Exercise Price, options outstanding	$0.51
Weighted Average Remaining Contractual Life	5 years 1 month 6 days
Number Exercisable	1,675,910
Weighted Average Exercise Price, options exercisable	$0.72
Weighted Average Remaining Contractual Life Options Exercisable	4 years 9 months 18 days

9_Stockholders_Deficit_Details3

9. Stockholders' (Deficit) (Details 3) (USD $)	12 Months Ended
	Dec. 31, 2014
Warrants November 2011
Contractual life, in years	60 months
Expected volatility	104.50%
Risk-free interest rate	0.88%
Exercise price	$0.81
Fair value per warrant	$0.54
Warrants Revalued December 2013
Contractual life, in years	34 months
Expected volatility	154.80%
Risk-free interest rate	0.78%
Exercise price	$0.25
Fair value per warrant	$0.21
Warrants Revalued December 2014
Contractual life, in years	22 months
Expected volatility	116.00%
Risk-free interest rate	0.58%
Exercise price	$0.25
Fair value per warrant	$0.15